<SEC-DOCUMENT>0001104659-24-005272.txt : 20240119
<SEC-HEADER>0001104659-24-005272.hdr.sgml : 20240119
<ACCEPTANCE-DATETIME>20240119170528
ACCESSION NUMBER:		0001104659-24-005272
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20240119
DATE AS OF CHANGE:		20240119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STANDARD BIOTOOLS INC.
		CENTRAL INDEX KEY:			0001162194
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				770513190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276626
		FILM NUMBER:		24546372

	BUSINESS ADDRESS:	
		STREET 1:		2 TOWER PLACE
		STREET 2:		SUITE 2000
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502666000

	MAIL ADDRESS:	
		STREET 1:		2 TOWER PLACE
		STREET 2:		SUITE 2000
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLUIDIGM CORP
		DATE OF NAME CHANGE:	20011113
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tm243480d1_s3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on January&nbsp;19, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-</B>&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-3&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STANDARD BIOTOOLS INC.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Delaware</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>77-0513190</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SomaLogic,&nbsp;Inc.
2009 Equity Incentive Plan<BR>
SomaLogic,&nbsp;Inc. 2017 Equity Incentive Plan<BR>
SomaLogic,&nbsp;Inc. 2021 Omnibus Incentive Plan&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Non-Statutory Stock
Option Agreement, dated June 6, 2014&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Non-Statutory Stock
Option Agreement, dated November 19, 2018</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Non-Statutory Stock
Option Agreement, dated September 1, 2020&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Non-Statutory Stock
Option Agreement, dated August 6, 2021</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Non-Statutory Stock
Option Agreement, dated August 20, 2021&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Full title of the plans)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Tower Place, Suite 2000&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>South San Francisco, CA&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(650) 266-6000&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone number,
including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Michael Egholm, Ph.D.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>President and Chief Executive Officer</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Tower Place, Suite 2000</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>South San Francisco, CA 94080</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(650) 266-6000&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>William C. Hicks, Esq.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>John T. Rudy, Esq.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>One Financial Center</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Boston, MA 02111</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(617) 542-6000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public: </B></FONT>From time to time after the effective date of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the only securities being registered on this Form&nbsp;are being offered pursuant to dividend or interest reinvestment plans, please
check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If any of the securities being registered on this
Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, check the following box. <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form&nbsp;is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act,
please check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form&nbsp;is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form&nbsp;is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule&nbsp;462(e)&nbsp;under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form&nbsp;is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule&nbsp;413(b)&nbsp;under the Securities Act, check the following
box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
 &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of Securities Act. &thinsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>THE REGISTRANT HEREBY
AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY&nbsp;BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH
SECTION&nbsp;8(a)&nbsp;OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE
AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION&nbsp;8(a), MAY&nbsp;DETERMINE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ff4040"><B>The information in this preliminary prospectus
is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange
Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state
where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #ff4040"><B>SUBJECT TO COMPLETION, DATED
JANUARY 19, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm243480d1_s3img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 13.5pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Standard BioTools Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,837,152 SHARES OF COMMON STOCK<BR>
ISSUABLE UPON EXERCISE OF AWARDS<BR>
under the<BR>
SOMALOGIC,&nbsp;INC. 2009 EQUITY INCENTIVE PLAN<BR>
SOMALOGIC,&nbsp;INC. 2017 EQUITY INCENTIVE PLAN<BR>
SOMALOGIC,&nbsp;INC. 2021 OMNIBUS INCENTIVE PLAN<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED JUNE 6, 2014<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED NOVEMBER 19, 2018<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED SEPTEMBER 1, 2020<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED AUGUST 6, 2021<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED AUGUST 20, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus is related to the 10,837,152 shares
of common stock, $0.001 par value per share (the &ldquo;Standard BioTools Common Stock&rdquo; or &ldquo;Common Stock&rdquo;), of Standard
BioTools Inc., a Delaware corporation (&ldquo;Standard BioTools&rdquo; or the &ldquo;Company&rdquo;), that may be issued upon the exercise
of stock options granted under certain equity plans of SomaLogic,&nbsp;Inc., a Delaware corporation (&ldquo;SomaLogic&rdquo;), to former
directors, employees and consultants of SomaLogic, as more fully described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The exercise price of the shares of Standard BioTools
Common Stock issuable upon the exercise of any stock option was determined at the time of grant of each stock option. A description of
the relevant equity plans begins on page 5 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">The shares
of Standard BioTools Common Stock are listed on The Nasdaq Global Select Market under the symbol &ldquo;LAB.&rdquo; On January&nbsp;18,
2024, the last reported sale price of the Standard BioTools Common Stock on The Nasdaq Global Select Market was $2.29 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white"><B>Investing
in these securities involves risks. You should read carefully this prospectus, the documents incorporated by reference in this prospectus
and any prospectus supplement before you invest. Please carefully read the information under the headings &ldquo;Risk Factors&rdquo; beginning
on page 3 of this prospectus and &ldquo;Item 1A &ndash; Risk Factors&rdquo; of our most recent report on Form&nbsp;10-K, as revised
or supplemented by our subsequent Quarterly Reports on Form&nbsp;10-Q,&nbsp;that are incorporated by reference in this prospectus before
you invest in our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>The date of this prospectus
is&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;, 2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS <SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Page</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_001">1</A></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_002">PROSPECTUS SUMMARY</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_002">2</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_003">RISK FACTORS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_003">3</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_004">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_004">4</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_005">DESCRIPTION OF THE PLANS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_005">5</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_006">U.S. FEDERAL INCOME TAX INFORMATION</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_006">11</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007">USE OF PROCEEDS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_007">13</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008">PLAN OF DISTRIBUTION</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_008">13</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_009">LEGAL MATTERS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_009">13</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010">EXPERTS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_010">13</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_011">WHERE YOU CAN FIND MORE INFORMATION</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_011">13</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_012">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_012">14</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">i</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus is part of a registration statement
that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January&nbsp;5, 2024 (the &ldquo;Effective
Time&rdquo;), pursuant to the Agreement and Plan of Merger, dated October&nbsp;4, 2023 (the &ldquo;Merger Agreement&rdquo;), by
and among the Company, SomaLogic, and Martis Merger Sub,&nbsp;Inc., a Delaware corporation and wholly owned subsidiary of the Company
(&ldquo;Merger Sub&rdquo;), Merger Sub merged with and into SomaLogic, with SomaLogic becoming a wholly owned subsidiary of the Company
(the &ldquo;Merger&rdquo;). References in this prospectus to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;Standard
BioTools&rdquo; are references to the Company and its consolidated subsidiaries, including SomaLogic, unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, at the Effective Time of the Merger, Standard BioTools assumed the SomaLogic 2009 Equity Incentive Plan (the
 &ldquo;2009 Plan&rdquo;), the SomaLogic 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;) and the SomaLogic 2021 Omnibus Incentive
Plan (the &ldquo;2021 Plan,&rdquo; and each, a &ldquo;SomaLogic Plan,&rdquo; and collectively, the &ldquo;SomaLogic Plans&rdquo;) and
each stock option under the SomaLogic Plans or granted outside of the SomaLogic Plans, whether or not issued under a SomaLogic Plan, to
the extent then outstanding and unexercised (each, a &ldquo;SomaLogic Stock Option&rdquo;). Standard BioTools does not plan to issue new
awards under any of the SomaLogic Plans. Each SomaLogic Stock Option assumed by the Company </FONT>was converted into a stock option to
acquire shares of Standard BioTools Common Stock. As of the Effective Time, the number of shares of Standard BioTools Common Stock underlying
each such assumed SomaLogic Stock Option was equal to the product of (i)&nbsp;the number of shares of SomaLogic common stock underlying
the applicable SomaLogic Stock Option immediately prior to the Effective Time multiplied by (ii)&nbsp;1.11 (the &ldquo;Exchange Ratio&rdquo;),
with the resulting number of shares of Standard BioTools Common Stock rounded down to next the nearest whole share, and the exercise price
per share of each such assumed SomaLogic Stock Option equal to (a)&nbsp;the per share exercise price applicable to such SomaLogic Stock
Option immediately prior to the Effective Time divided by (b)&nbsp;the Exchange Ratio, with the resulting exercise price per share rounded
up to the next nearest whole cent. Except as noted above, each assumed and converted SomaLogic Stock Option will continue to be governed
by substantially the same terms and conditions as were applicable to such SomaLogic Stock Option immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A number of SomaLogic Stock Options issued prior
to the Merger to individuals who were eligible participants of the SomaLogic Plans at the time of grant but who were no longer employed
by, or no longer provided service to, SomaLogic at the Effective Time remained outstanding as of the Effective Time and were so assumed
and converted by the Company (the &ldquo;Former Service Provider Awards&rdquo;). Along with other outstanding awards, the Former Service
Provider Awards continue to be governed by the terms of the applicable SomaLogic Plan and the specific terms and conditions under which
such awards were granted, except for modifications to the number of shares and exercise price for the assumed awards as a result of application
of the Exchange Ratio conversion formula discussed above. This registration statement registers the Standard BioTools Common Stock to
be issued upon the exercise of stock options covered by the Former Service Provider Awards so assumed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus provides you with a general description
of the relevant information with respect to Former Service Provider Awards issued under the SomaLogic Plans. Statements contained herein
concerning the provisions of certain documents are necessarily summaries of such documents, and each statement is qualified in its entirety
by reference to the copy of the applicable document filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should read this prospectus, any prospectus
supplement to this prospectus, any documents that we incorporated by reference in this prospectus and any prospectus supplement and the
additional information described below under &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Documents
by Reference&rdquo; before making an investment decision. You should rely only on the information contained or incorporated by reference
in this prospectus and any prospectus supplement. We have not authorized any other person to provide you with different information. If
anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities
in any jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should not assume that the information in
this prospectus, any accompanying prospectus supplement or any documents we incorporate by reference in this prospectus and any prospectus
supplement is accurate as of any date other than the date on the front of those documents. Our business, financial condition, results
of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<DIV STYLE=" border: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; padding-top: 8pt; padding-bottom: 8pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Standard BioTools is driven by a bold purpose&thinsp;&mdash;&thinsp;unleashing
tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation
high resolution technologies that assist biomedical researchers to develop medicines faster and better. Standard BioTools&rsquo; tools
are designed to provide reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics
technologies, which are useful in proteomics and genomics that help transform scientific discoveries into better patient outcomes. Standard
BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories
worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Background on the Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On October&nbsp;4, 2023, Standard BioTools entered
into the Merger Agreement with SomaLogic and Merger Sub, <FONT STYLE="background-color: white">pursuant to which, at the Effective Time,
among other matters, Merger </FONT>Sub merged with and into SomaLogic, with SomaLogic surviving as a wholly owned subsidiary of Standard
BioTools. <FONT STYLE="background-color: white">Upon the terms and subject to the conditions set forth in the Merger Agreement, at the
Effective Time, each share of common stock, par value $0.0001 per share (&ldquo;SomaLogic Stock&rdquo;), converted into the right to receive
1.11 shares of Standard BioTools Common Stock, pursuant to the Exchange Ratio. At the Effective Time, SomaLogic&rsquo;s common stockholders
owned approximately 57%, and Standard BioTools&rsquo; common stockholders owned approximately 43%, of the outstanding shares of common
stock of the combined company on a fully diluted basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as of the Effective Time, Standard BioTools assumed the SomaLogic Plans and outstanding SomaLogic Stock Options and restricted
stock units convertible into shares of SomaLogic Stock (&ldquo;SomaLogic RSUs&rdquo; and together with the SomaLogic Stock Options, the
 &ldquo;Equity Awards&rdquo;), whether vested or unvested. Each such Equity Award so assumed by the Company continued to have, and be subject
to, the same terms and conditions applicable to such Equity Award immediately prior to the Effective Time, except that (A)&nbsp;such SomaLogic
Stock Option is now exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of SomaLogic
Stock subject to such SomaLogic Stock Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down
to the next nearest share of Standard BioTools Common Stock, (B)&nbsp;the exercise price per share is now the exercise price per share
in effect for that SomaLogic Stock Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the
next nearest cent and (C)&nbsp;such SomaLogic RSU vested for that number of shares of Standard BioTools Common Stock equal to the number
of shares of SomaLogic Stock subject to such SomaLogic RSU immediately prior to the Effective Time multiplied by the Exchange Ratio and
rounded to the next nearest share of Standard BioTools Common Stock. In addition, as of the Effective Time, each SomaLogic warrant, each
exercisable for one share of SomaLogic Stock, was treated in accordance with its terms </FONT>and each warrant will convert into the right
to receive, upon exercise of such Warrant, the number of shares of Standard BioTools Common Stock equal to multiplying the number of shares
of common stock of SomaLogic subject to such warrant by the Exchange Ratio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate History and Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We were incorporated in California in May&nbsp;1999
as &ldquo;Mycometrix Corporation&rdquo;, changed our name to &ldquo;Fluidigm Corporation&rdquo; in April&nbsp;2001, reincorporated in
Delaware in July&nbsp;2007, and subsequently changed our name to &ldquo;Standard BioTools Inc.&rdquo; in April&nbsp;2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our principal executive offices are located at
2 Tower Place, South San Francisco, California 94080. Our telephone number is (650) 266-6000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We make available on our website, free of charge,
our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, and any amendments to those
reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our SEC reports
can be accessed through the investor relations page&nbsp;of our website. The SEC also maintains an Internet site at <I>www.sec.gov</I>
that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Standard BioTools Common Stock is listed on
the Nasdaq Global Select Market under the symbol &ldquo;LAB.&rdquo;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An investment in our securities involves a high
degree of risk. Before you invest in our securities you should carefully consider those risk factors described under, but not limited
to, the heading &ldquo;Risk Factors&rdquo; in our most recent Annual Report on Form&nbsp;10-K, any subsequently filed Quarterly Reports
on Form&nbsp;10-Q and any subsequently filed Current Reports on Form&nbsp;8-K (other than, in each case, information furnished rather
than filed), which are incorporated by reference herein, and those risk factors that may be included in any applicable prospectus supplement,
together with all of the other information included in this prospectus, any prospectus supplement and the documents we incorporate by
reference. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently
known to us or that we currently deem immaterial may also affect our operations. If any of these risks were actually to occur, our business,
financial condition or results of operations could be materially adversely affected. In that case, the value of our securities could decline,
and you could lose part or all of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus and the information incorporated
by reference in this prospectus contain certain statements that constitute &ldquo;forward-looking statements&rdquo; within the meaning
of Section&nbsp;27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). The words &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;expect,&rdquo; &ldquo;could,&rdquo;
 &ldquo;would,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo; &ldquo;potentially,&rdquo; &ldquo;likely,&rdquo; and similar expressions
and variations thereof are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements.
Forward-looking statements include, but are not necessarily limited to, those relating to: the anticipated benefits of the Merger, the
future financial performance of the combined company, information concerning our possible or assumed future cash flow, revenue, sources
of revenue and results of operations, cost of product revenue and product margin, operating and other income and expenses, unit sales
and the selling prices of our products, business strategies, financing plans, expansion of our business, competitive position, industry
environment, potential growth opportunities, market growth expectations, and the effects of competition and public health crises on our
business, the global supply chain, and our customers, suppliers, and other business partners. Those statements appear in this prospectus,
any accompanying prospectus supplement and the documents incorporated herein and therein by reference, particularly in the sections captioned
 &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and include statements regarding the intent, belief or current expectations of our management that are subject to known and unknown risks,
uncertainties and assumptions. You are cautioned that any such forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements
as a result of various factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements
as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur
and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law,
including the securities laws of the United States and the rules&nbsp;and regulations of the SEC, we do not plan to publicly update or
revise any forward-looking statements contained herein after we distribute this prospectus, whether as a result of any new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, statements that &ldquo;we believe&rdquo;
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available
to us as of the date of this prospectus, and although we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review
of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly
rely upon these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus and the documents incorporated
by reference in this prospectus may contain market data that we obtain from industry sources. These sources do not guarantee the accuracy
or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information.
The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable
and sound as of the date of this prospectus, actual results may differ from the projections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_005"></A>DESCRIPTION
OF THE PLANS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SomaLogic,&nbsp;Inc. 2009 Equity Incentive Plan&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SomaLogic,&nbsp;Inc. 2017 Equity Incentive Plan&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SomaLogic,&nbsp;Inc. 2021 Omnibus Incentive Plan&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-Statutory Stock Option Agreement, dated June 6,
2014&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-Statutory Stock Option Agreement, dated November 19,
2018&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-Statutory Stock Option Agreement, dated September 1,
2020&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-Statutory Stock Option Agreement, dated August 6,
2021&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-Statutory Stock Option Agreement, dated August 20, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</FONT>Company assumed and adopted each of the SomaLogic Plans, the Non-Statutory Stock Option Agreement, dated June&nbsp;6, 2014 (the
 &ldquo;2009 Plan Stand-Alone Award&rdquo;), and each of the Non-Statutory Stock Option Agreement, dated November&nbsp;19, 2018, the Non-Statutory
Stock Option Agreement, dated September&nbsp;1, 2020, the Non-Statutory Stock Option Agreement, dated August&nbsp;6, 2021 and the Non-Statutory
Stock Option Agreement, dated August&nbsp;20, 2021 (the &ldquo;Non-Plan Awards&rdquo; and together with the SomaLogic Plans, the &ldquo;Plans&rdquo;).
Each of the SomaLogic Stock Options issued under the Plans and assumed by the Company was converted into a stock option to acquire shares
of Standard BioTools Common Stock. Standard BioTools does not plan to issue new awards under any of the Plans. Accordingly, only certain
provisions of the Plans continue to be relevant to the remaining Former Service Provider Awards, as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Administration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Plans are administered by the Compensation
Committee (the &ldquo;Compensation Committee&rdquo;) of the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Rules&nbsp;of Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Awards under the Plans are evidenced by an agreement.
Any Awards as to which the applicable vesting or payment conditions have not been satisfied will be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transferability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Awards granted pursuant to the Plans are generally
nontransferable except by will or the laws of descent and distribution. The 2017 Plan and 2021 Plan also explicitly provide that no person
has or may create a lien on any Awards under the Plan. Awards are exercisable (i)&nbsp;during the participant&rsquo;s lifetime only by
the participant or (ii)&nbsp;in the event of the participant&rsquo;s death by the legal representative of the participant&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Option Exercises and Term</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares and exercise price for the </FONT>Former Service Provider Awards has been modified from that stated in the individual
award agreements by the application of the Exchange Ratio conversion formula discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided below under the heading &ldquo;Recapitalizations and Reorganizations,&rdquo; with respect to options granted under the 2009
Plan, </FONT>2009 Plan Stand-Alone Award or 2017 Plan, the exercise price per share of an option may not be reduced after the date of
grant and an option cannot be cancelled or surrendered in exchange for an option with a lower exercise price per share or in exchange
for cash or other consideration. Notwithstanding the foregoing, the 2021 Plan expressly provides that the exercise price per share of
an option may be reduced after the date of grant and/or an option to be cancelled or surrendered in exchange for an option with a lower
exercise price per share or in exchange for cash or other consideration, in either case, subject to the terms and conditions and within
the limitations of the 2021 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The 2021 Plan provides that the Compensation Committee
may permit an option exercise price to be paid (i)&nbsp;in cash or by check, bank draft or money order payable to the order of the Company;
(ii)&nbsp;solely to the extent permitted by applicable law, if the Common Stock is traded on a national securities exchange, and the Compensation
Committee authorizes, through a procedure whereby the participant delivers irrevocable instructions to a broker reasonably acceptable
to the Compensation Committee to deliver promptly to the Company an amount equal to the purchase price; or (iii)&nbsp;on such other terms
and conditions as may be acceptable to the Compensation Committee (including, without limitation, having the Company withhold shares of
Common Stock issuable upon exercise of the option, or by payment in full or in part in the form of Common Stock owned by the participant,
based on the fair market value of the Common Stock on the payment date as determined by the Compensation Committee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The 2017 Plan provides that the Compensation Committee
may permit an option exercise price to be paid (i)&nbsp;in cash or by check, bank draft or money order payable to the Company; (ii)&nbsp;pursuant
to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock
subject to the option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay
the aggregate exercise price to the Company from the sales proceeds; (iii)&nbsp;by delivery to the Company (either by actual delivery
or attestation) of shares of Common Stock; or (iv)&nbsp;if an option is a nonstatutory stock option, by a &ldquo;net exercise&rdquo; arrangement
pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares
with a fair market value that does not exceed the aggregate exercise price; provided, however, that the Company will accept a cash or
other payment from the participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction
in the number of whole shares to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2009 Plan and </FONT>2009 Plan Stand-Alone Award provide that the Compensation Committee may permit an option exercise price to be paid
(i)&nbsp;in cash or (ii)&nbsp;in such other manner as the Compensation Committee may permit, including by (A)&nbsp;withholding shares
of Common Stock otherwise issuable to the participant upon exercise of the option, (B)&nbsp;delivery to the Company of shares of Common
Stock (by actual delivery or attestation) already owned by the participant, (C)&nbsp;delivery of a promissory note made payable by the
participant to the Company containing such terms and conditions as may be specified by the Compensation Committee, or a combination thereof,
unless otherwise provided in the Award agreement. Any promissory note the Compensation Committee may agree to accept as payment of the
exercise price of an option will be secured by the shares of Common Stock subject to the option and such other collateral as the Compensation
Committee may deem acceptable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Non-Plan Awards provide that the option exercise
price be paid (i)&nbsp;in cash or by check, bank draft or money order payable to the Company; (ii)&nbsp;by delivery to the Company of
shares of Common Stock (by actual delivery or attestation) already owned by the participant; or (iii)&nbsp;by withholding shares of Common
Stock otherwise issuable to the participant upon exercise of the option, subject to discretion by the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The term of an option may not exceed ten years
from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Treatment of Awards upon Termination of Employment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The terms of particular Awards may provide that
they terminate, among other reasons, upon the holder&rsquo;s termination of employment or other status with respect to the Company (with
or without cause), upon a specified date, upon the holder&rsquo;s death or disability, or upon the occurrence of a change in control of
the Company. Awards may also include exercise, conversion or settlement rights for a holder&rsquo;s estate or personal representative
in the event of the holder&rsquo;s death or disability. Nothing in the Plan or in any Award confers upon any participant the right to
continue as an employee, officer, director or consultant of the Company or any of its affiliates or affects the right of the Company or
any of its affiliates to terminate the participant&rsquo;s employment or services at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recapitalizations and Reorganizations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Plans provide that in the event of a nonreciprocal
transaction between the Company and the holders of Common Stock that changes the value per share of Common Stock, such as a stock dividend,
stock split, spinoff, rights offering or recapitalization through a large, non-recurring dividend, the number of shares subject the Plans,
the number of shares subject to each outstanding Award, and the exercise or threshold price of the shares underlying outstanding Awards
will be proportionately adjusted. The Compensation Committee may choose one or more permitted approaches with respect to outstanding Awards
in the event of a &ldquo;change in control&rdquo;. The grant of any Award pursuant to the Plan does not affect in any way the Company&rsquo;s
right or power to make adjustments, reclassifications, reorganizations or changes to its capital or business structure, or to merge, consolidate,
issue debt or equity securities having preferences or priorities over Common Stock, dissolve, liquidate, sell or transfer all or any part
of its business or assets, or to undertake any other corporate act or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the 2021 Plan, in the event of a &ldquo;change
in control&rdquo;, the Compensation Committee may elect to treat Awards in accordance with one or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards, whether or not then vested, may be continued, assumed, or have new rights substituted therefor, as determined by the Committee
in a manner consistent with the requirements of applicable law, and any restrictions to which such Awards were subject will not lapse.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards may be cancelled in exchange for payment by the Company or an affiliate of an amount of cash equal to the excess (if any) of
the highest price per share of Common Stock paid in relation to the &ldquo;change in control&rdquo; multiplied by the number of shares
of Common Stock covered by such Awards, over the aggregate exercise price of such Awards. For clarity, if there is no excess, Awards may
be cancelled without any payment therefor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>All outstanding and unexercised Awards that provide for a participant elected exercise may be terminated effective as of the date
of the &ldquo;change in control&rdquo;, by delivering notice of such termination to each participant at least twenty (20) days prior to
the date of consummation of the &ldquo;change in control&rdquo;, and allowing each such participant to exercise in full all of such participant&rsquo;s
Awards that are then outstanding, contingent on the occurrence of the &ldquo;change in control&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>The Compensation Committee may elect to accelerate vesting or cause a lapse of restrictions with respect to any Award.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise provided in an Award agreement,
a &ldquo;change in control&rdquo; is generally deemed to occur under the 2021 Plan if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>any &ldquo;person&rdquo; (as limited in the 2021 Plan) becomes the beneficial owner of securities of the Company representing 50%
or more of the combined voting power of the Company&rsquo;s then outstanding securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>during any two consecutive years, individuals who at the beginning of such period constitute the Board, and any new director (other
than certain directors identified in the 2021 Plan) whose election by the Board or nomination for election by the Company&rsquo;s stockholders
was approved by a vote of at least two-thirds of the applicable directors, cease to constitute at least a majority of the Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>a merger or consolidation of the Company with any other corporation is consummated; provided, however that neither a merger or consolidation
(i)&nbsp;which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent more
than 50% of the combined voting power of the voting securities of the Company or such surviving entity outstanding immediately after such
merger or consolidation nor (ii)&nbsp;effected to implement a recapitalization of the Company (or similar transaction) in which no person
(as limited in the 2021 Plan) acquires more than 50% of the combined voting power of the Company&rsquo;s then outstanding securities shall
constitute a change in control; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>a complete liquidation or dissolution of the Company or the consummation of a sale or disposition by the Company of all or substantially
all of the Company&rsquo;s assets; provided, however that the sale or disposition of all or substantially all of the assets of the Company
to a person or persons who beneficially own, directly or indirectly, 50% or more of the combined voting power of the outstanding voting
securities of the Company at the time of the sale shall not constitute a change in control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the 2017 Plan, in the event of a &ldquo;change
in control&rdquo;, the Compensation Committee may elect to treat Awards in accordance with one or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards may be assumed by the surviving or acquiring entity or substituted with a similar award.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>With respect to any reacquisition or repurchase rights held by the Company with respect to Common Stock issued pursuant to the Award,
the Compensation Committee may either arrange for the assignment thereof to the surviving or acquiring entity or the lapse, in whole or
in part, thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Vesting, in whole or in part, and exercisability may be accelerated to a date prior to the effective time of the &ldquo;change in
control&rdquo;, with such Award terminating if not exercised (if applicable) at or prior to the effective time of the &ldquo;change in
control&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards may be cancelled, to the extent not vested or not exercised prior to the effective time of the &ldquo;change in control&rdquo;,
in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Payment may be made, in such form as may be determined by the Board equal to the excess, if any, of (i)&nbsp;the value of the property
the participant would have received upon the exercise of the Award immediately prior to the effective time of the &ldquo;change in control&rdquo;,
over (ii)&nbsp;any exercise price payable by the participant in connection with such exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise provided in an Award agreement,
a &ldquo;change in control&rdquo; is generally deemed to occur under the 2017 Plan if in a single transaction or in a series of related
transactions, of any one or more of the following events occurs, with certain exceptions set forth in the 2017 Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>any &ldquo;exchange act person&rdquo; (as defined in the 2017 Plan) becomes the &ldquo;owner&rdquo; (as defined in the 2017 Plan),
directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&rsquo;s then
outstanding securities other than by virtue of a merger, consolidation or similar transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately
after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto
do not own, directly or indirectly, either (i)&nbsp;outstanding voting securities representing more than 50% of the combined outstanding
voting power of the surviving entity in such merger, consolidation or similar transaction or (ii)&nbsp;more than 50% of the combined outstanding
voting power of the parent of the surviving entity in such merger, consolidation or similar transaction, in each case in substantially
the same proportions as their ownership of the outstanding voting securities of the Company immediately prior to such transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets
of the Company and its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated
assets of the Company and its subsidiaries to an entity, more than fifty percent (50%) of the combined voting power of the voting securities
of which are owned by stockholders of the Company in substantially the same proportions as their ownership of the outstanding voting securities
of the Company immediately prior to such sale, lease, license or other disposition; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>individuals who, on the date the 2017 Plan is adopted by the Board, are members of the Board cease for any reason to constitute at
least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any
new Board member was approved or recommended by a majority vote of the members of the Board on the date the 2017 Plan is adopted by the
Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Board on the date the 2017
Plan is adopted by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2009 Plan and the </FONT>2009 Plan Stand-Alone Award, in the event of a &ldquo;change in control&rdquo;, the Compensation Committee
may elect to treat Awards in accordance with one or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards may be continued, assumed or replaced in whole or in part; provided, however, that if Awards are continued, assumed or replaced
and the participant&rsquo;s service is involuntarily terminated without &ldquo;cause&rdquo; (as defined in the 2009 Plan), outstanding
Awards shall vest in full, and if applicable, become immediately exercisable and remain exercisable for one year following such termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards may become vested and exercisable for such period of time prior to the effective time of the &ldquo;change in control&rdquo;
as is deemed fair and equitable by the Compensation Committee, and shall terminate at the effective time of the &ldquo;change in control
pursuant to notice of the same and subject to consummation of the &ldquo;change in control&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards may be required to be surrendered at or immediately prior to the effective time of the &ldquo;change in control&rdquo; in exchange
for payment of an amount equal to the difference, if any, between (i)&nbsp;the fair market value (as determined in good faith by the Compensation
Committee) of the consideration that would otherwise be received in the &ldquo;change in control&rdquo; for the number of shares of Common
Stock subject to the Award, and (ii)&nbsp;the aggregate exercise price (if any) for the Common Stock subject to such Award.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in an Award agreement, a &ldquo;change in control&rdquo; is deemed to occur under the 2009 Plan and the </FONT>2009
Plan Stand-Alone Award if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>any &ldquo;person&rdquo; (as limited in the 2009 Plan) becomes the beneficial owner of equity securities of the Company representing
more than 50% of the combined voting power of the Company&rsquo;s then outstanding securities entitled to vote generally in the election
of directors (&ldquo;voting securities&rdquo;), except that (i)&nbsp;any acquisition of Company equity securities by a person directly
from the Company for the purpose of providing financing to the Company, any formation of a group for the purpose of acquiring, holding,
or disposing of securities of the Company consisting solely of beneficial owners of the Company&rsquo;s voting securities as of the effective
date of the 2009 Plan, or any repurchase or other acquisition by the Company of its equity securities that causes any person to become
the beneficial owner of more than 50% of the Company&rsquo;s voting securities, will not be considered a change in control unless and
until, in either case, such Person acquires beneficial ownership of additional Company voting securities after the person initially became
the beneficial owner of more than 50% of the Company&rsquo;s voting securities by one of the means described in this clause (i); and (ii)&nbsp;a
change in control will occur if a person becomes the beneficial owner of more than 50% of the Company&rsquo;s voting securities as the
result of a (1)&nbsp;sale or other disposition of all or substantially all of the assets of the Company or (2)&nbsp;merger, consolidation,
share exchange, or similar transaction involving the Company, regardless of whether the Company is the surviving corporation (either,
a &ldquo;Corporate Transaction&rdquo;) only if the Corporate Transaction is itself a change in control;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>individuals who (i)&nbsp;are, as of the effective date of the 2009 Plan, directors of the Company, (ii)&nbsp;who are elected as directors
of the Company subsequent to the effective date of the 2009 Plan pursuant to a nomination or board representation right of preferred stockholders
of the Company, or (iii)&nbsp;become directors of the Company after the effective date of the 2009 Plan and whose initial election, or
nomination for election by the Company&rsquo;s stockholders, was approved by at least a majority of the applicable directors cease for
any reason to constitute a majority of the members of the Board; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>the consummation of a Corporate Transaction unless, immediately following such Corporate Transaction, all or substantially all of
the persons who were the beneficial owners of Company voting securities immediately prior to such Corporate Transaction beneficially own,
directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities (or comparable equity interests)
of the surviving or acquiring entity (or its parent company) resulting from such Corporate Transaction in substantially the same proportions
as their ownership of Company voting securities immediately prior to such Corporate Transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the Non-Plan Awards, in the event of a &ldquo;change
in control&rdquo; that is also a &ldquo;Corporate Transaction,&rdquo; the Compensation Committee may elect to treat Awards in accordance
with one or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards may be continued, assumed or replaced in whole or in part;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>If and to the extent that the Award is not continued, assumed or replaced in connection with a Corporate Transaction, then the Award
shall become fully exercisable for such period of time prior to the effective time of the Corporate Transaction as is deemed fair and
equitable by the Compensation Committee, and shall terminate at the effective time of the Corporate Transaction subject to consummation
of Corporate Transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Awards may be required to be surrendered at or immediately prior to the effective time of the Corporate Transaction in exchange for
payment of an amount equal to the difference, if any, between (i)&nbsp;the fair market value (as determined in good faith by the Compensation
Committee) of the consideration that would otherwise be received in the Corporate Transaction for the number of shares of Common Stock
subject to the Award, and (ii)&nbsp;the aggregate exercise price (if any) for the Common Stock subject to such Award.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise provided in an Award agreement,
a &ldquo;change in control&rdquo; is deemed to occur under the Non-Plan Awards if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>any &ldquo;person&rdquo; (as limited in the Award) becomes the beneficial owner of equity securities of the Company representing more
than 50% of the combined voting power of the Company&rsquo;s then outstanding securities entitled to vote generally in the election of
directors (&ldquo;voting securities&rdquo;), except that (i)&nbsp;any acquisition of Company equity securities by a person directly from
the Company for the purpose of providing financing to the Company, any formation of a group for the purpose of acquiring, holding, or
disposing of securities of the Company consisting solely of beneficial owners of the Company&rsquo;s voting securities as of the effective
date of the Award, or any repurchase or other acquisition by the Company of its equity securities that causes any person to become the
beneficial owner of more than 50% of the Company&rsquo;s voting securities, will not be considered a change in control unless and until,
in either case, such Person acquires beneficial ownership of additional Company voting securities after the person initially became the
beneficial owner of more than 50% of the Company&rsquo;s voting securities by one of the means described in this clause (i); and (ii)&nbsp;a
change in control will occur if a person becomes the beneficial owner of more than 50% of the Company&rsquo;s voting securities as the
result of a (1)&nbsp;sale or other disposition of all or substantially all of the assets of the Company or (2)&nbsp;merger, consolidation,
share exchange, or similar transaction involving the Company, regardless of whether the Company is the surviving corporation (either,
a &ldquo;Corporate Transaction&rdquo;) only if the Corporate Transaction is itself a change in control;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>individuals who (i)&nbsp;are, as of the effective date of the Award, directors of the Company, (ii)&nbsp;who are elected as directors
of the Company subsequent to the effective date of the Award pursuant to a nomination or board representation right of preferred stockholders
of the Company, or (iii)&nbsp;become directors of the Company after the effective date of the Award and whose initial election, or nomination
for election by the Company&rsquo;s stockholders, was approved by at least a majority of the applicable directors cease for any reason
to constitute a majority of the members of the Board; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>the consummation of a Corporate Transaction unless, immediately following such Corporate Transaction, all or substantially all of
the persons who were the beneficial owners of Company voting securities immediately prior to such Corporate Transaction beneficially own,
directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities (or comparable equity interests)
of the surviving or acquiring entity (or its parent company) resulting from such Corporate Transaction in substantially the same proportions
as their ownership of Company voting securities immediately prior to such Corporate Transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Requests for additional information regarding
the Plans and its administration should be directed to Standard BioTools,&nbsp;Inc., 2 Tower Place, Suite&nbsp;2000, South San Francisco,
CA 94080, telephone (650) 266-6000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>U.S.
FEDERAL INCOME TAX INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following discussion outlines generally the
federal income tax consequences of participation in the Plans and should not be construed as legal, tax, or investment advice. The federal
income tax law and regulations are frequently amended, and individual circumstances may vary these results. Although the Company may endeavor
to structure an Award under the Plans to receive favorable U.S. or foreign tax treatment or to avoid adverse tax treatment (e.g., under
Code Section&nbsp;409A), the Company makes no representation or covenant to that effect, makes no representation or covenant that such
tax treatment will apply and expressly disavows any covenant to maintain favorable tax treatment or avoid unfavorable tax treatment. All
participants should consult their own tax counsel for advice regarding the specific tax consequences applicable to them, including federal,
state and local tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Qualified Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A participant will not recognize income upon the
grant of a non-qualified stock option. At the time the participant exercises a non-qualified stock option or portion thereof, the participant
will recognize compensation taxable as ordinary income in an amount equal to the excess of the fair market value of the Common Stock on
the date the non-qualified stock option is exercised over the price paid for the Common Stock, and the Company will then be entitled to
a corresponding deduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the period the shares of Common Stock are held by a participant after exercise, the sale or other taxable </FONT><FONT STYLE="background-color: white">disposition</FONT>
of shares acquired through the exercise of a non-qualified stock option generally will result in a short-term or long-term capital gain
or loss equal to the difference between the amount realized on the disposition and the fair market value of the shares when the non-qualified
stock option was exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code Section&nbsp;409A Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</FONT><FONT STYLE="background-color: white">income</FONT> tax treatment described above in this &ldquo;Federal Income Tax Consequences&rdquo;
section is correct if the agreements governing the applicable Award, and the manner in which the Award is operated, are compliant with
or exempt from Code Section&nbsp;409A. While the Company intends all Awards under the Plans to comply with or be exempt from Code Section&nbsp;409A,
it can not guarantee that. If the Award is not exempt from Code Section&nbsp;409A and Code Section&nbsp;409A is not complied with, the
participant will face tax consequences different from those described above. In that case, the participant will recognize compensation
taxable as ordinary income as soon as the compensation is no longer subject to a &ldquo;substantial risk of forfeiture&rdquo; within the
meaning of Code Section&nbsp;409A, and the tax will be increased by 20% plus an interest component.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code Section&nbsp;162(m)&nbsp;Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
</FONT><FONT STYLE="background-color: white">Section</FONT>&nbsp;162(m)&nbsp;provides that no deduction will be allowed for applicable
employee remuneration with respect to a &ldquo;covered employee&rdquo; (i.e., the chief executive officer, the chief financial officer
or an executive officer who is one of the three highest paid officers of the Company other than the chief executive officer and the chief
financial officer) to the extent such remuneration exceeds $1,000,000. Code Section&nbsp;162(m)&nbsp;provides an exception from the deduction
limit for compensation payable solely on account of the attainment of one or more performance goals, subject to certain requirements,
for remuneration pursuant to a binding written contract that was in effect on November&nbsp;2, 2017 or as to which transition relief from
the changes made to Code Section&nbsp;162(m)&nbsp;by the Tax Cuts and Jobs Act of 2017 is otherwise available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code Section&nbsp;280G and Code Section&nbsp;4999 Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under</FONT>
Code Sections 280G and 4999, the Company may not deduct any &ldquo;excess parachute payments&rdquo; to certain individuals (including
certain corporate officers), and such individuals must pay a 20% excise tax on any &ldquo;excess parachute payment.&rdquo; An individual&rsquo;s
 &ldquo;parachute payments&rdquo; which exceed his or her average annual compensation for the five years preceding the year in which a
change in control occurs will generally be treated as &ldquo;excess parachute payments&rdquo; if the present value of such payments equals
or exceeds three times the individual&rsquo;s average annual compensation for the five years preceding the year in which a change in control
occurs. A payment generally may be considered a &ldquo;parachute payment&rdquo; if it is contingent on a change in control of the Company
and may include payments attributable to acceleration of Awards upon a change in control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tax Withholding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To the extent necessary or required by law, all
payments made pursuant to the Plans will be subject to income and other tax withholding. The Company has the right to require the participant
to remit the required tax withholding as a condition to payment of an Award. Tax withholding will be handled in the manner specified in
the applicable Award agreement, which may, if so provided, include paying the tax withholding by reducing the number of shares of Common
Stock the participant will receive by a number of shares with a fair market value equal to the required tax withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ERISA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Plan is not subject to the Employee Retirement
Income Security Act of 1974, nor is it qualified under Code Section&nbsp;401(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
</FONT><FONT STYLE="background-color: white">will</FONT> receive the exercise price of certain stock-based awards under the SomaLogic
Plans if and when such SomaLogic Stock Options are exercised for cash. We will not receive any proceeds if the SomaLogic Stock Options
are exercised on a cashless basis. We currently have no specific plans for the use of the net proceeds received upon exercise of such
SomaLogic Stock Options. We anticipate that we will use the net proceeds received by us for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are registering 10,837,152 shares of Standard BioTools Common Stock issuable upon the exercise of the SomaLogic Stock Options held by
</FONT>former directors, employees and consultants <FONT STYLE="background-color: white">of SomaLogic who are not, and have not been,
employees of the Company. The shares of Standard BioTools Common Stock offered by this prospectus are listed on The Nasdaq Global Select
Market. We do not plan to issue new awards under the SomaLogic Plans. The terms of the SomaLogic Plans and Merger Agreement permit us
to issue shares of our Standard BioTools Common Stock (or, in certain cases, the cash equivalent thereof) in connection with the exercise
of the SomaLogic Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_009"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C., Boston, Massachusetts, will pass upon the validity of the Standard BioTools Common Stock offered by this prospectus on behalf of
Standard BioTools Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
</FONT>financial <FONT STYLE="background-color: white">statements of Standard BioTools Inc. and management&rsquo;s assessment of the effectiveness
of internal control over financial reporting (which is included in Management&rsquo;s Report on Internal Control over Financial Reporting)
incorporated in this prospectus by reference to&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000116219423000013/fldm-20221231.htm" STYLE="-sec-extract: exhibit">Standard BioTools&rsquo; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2022</A>&nbsp;have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting
firm, given on the authority of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of SomaLogic appearing in&nbsp;</FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1837412/000162828023009564/slgc-20221231.htm">SomaLogic&rsquo;s Annual Report (Form&nbsp;10-K) for the year ended December&nbsp;31, 2022</A>, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth
in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated
herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_011"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&rsquo;s
website at <I>www.sec.gov</I>. Copies of certain information filed by us with the SEC are also available on our website at <I>http://www.standardbio.com</I>.
Information accessible on or through our website is not a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">This prospectus and any
prospectus supplement is part of a registration statement that we filed with the SEC and do not contain all of the information in the
registration statement. You should review the information and exhibits in the registration statement for further information on us and
our consolidated subsidiaries and the securities that we are offering. Forms of any documents establishing the terms of the offered securities
are filed as exhibits to the registration statement of which this prospectus forms a part or under cover of a Current Report on Form&nbsp;8-K
and incorporated in this prospectus by reference. Statements in this prospectus or any prospectus supplement about these documents are
summaries and each statement is qualified in all respects by reference to the document to which it refers. You should read the actual
documents for a more complete description of the relevant matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_012"></A>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">Th<FONT STYLE="background-color: white">e
SEC allows us to &ldquo;incorporate by reference&rdquo; into this prospectus information that we file with the SEC. This permits us to
disclose important information to you by referring to these filed documents. Any information referenced this way is considered to be a
part of this prospectus and any such information filed by us with the SEC subsequent to the date of this prospectus will automatically
be deemed to update and supersede this prospectus. We incorporate by reference into this prospectus and any accompanying prospectus supplement
the following documents that we have already filed with the SEC except that any information which is furnished under Item 2.02 or Item
7.01 of any Current Report on Form&nbsp;8-K (including financial statements or exhibits relating thereto furnished pursuant to Item 9.01)
and not filed shall not be deemed incorporated by referenced herein:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000116219423000013/fldm-20221231.htm">Form&nbsp;10-K</A> for the fiscal year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;14, 2023;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2023, June&nbsp;30, 2023 and September&nbsp;30,
2023, filed with the SEC on<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000116219423000024/lab-20230331.htm"> May&nbsp;9, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000162828023028287/lab-20230630.htm">August&nbsp;8, 2023</A> and<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000095017023060385/lab-20230930.htm">&nbsp;November&nbsp;7, 2023</A>, respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1162194/000095014223001246/eh230354030_def14a.htm">Schedule 14A</A>, filed with the SEC on April&nbsp;28, 2023 (excluding those portions that are not incorporated
by reference into our <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000116219423000013/fldm-20221231.htm">Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2022</A>);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">our Current Reports on Form&nbsp;8-K, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000095014223000674/eh230338628_8k.htm">March&nbsp;13,
                                                                                                                                                                                                                 2023</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000095014223000726/eh230339748_8k.htm">March&nbsp;16,
                                                                                                                                                                                                                 2023</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000095014223001328/eh230355478_8k.htm">May&nbsp;3,
                                                                                                                                                                                                                 2023</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000095014223001458/eh230358911_8k.htm">May&nbsp;15,
                                                                                                                                                                                                                 2023</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000116219423000033/lab-20230614.htm">June&nbsp;16,
                                                                                                                                                                                                                 2023</A>,<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000116219423000053/lab-20230724.htm">&nbsp;July&nbsp;28,
                                                                                                                                                                                                                 2023</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465923106606/tm2327474d1_8k.htm">October&nbsp;4, 2023</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465923120363/tm2331299d1_8k.htm">November&nbsp;21,
                                                                                                                                                                                                                 2023</A><FONT STYLE="color: blue"><U>,</U></FONT> <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465923123266/tm2332070d1_8k.htm">December&nbsp;4,
                                                                                                                                                                                                                 2023</A><FONT STYLE="color: blue">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465923127352/tm2333207d1_8k.htm">December&nbsp;19,
                                                                                                                                                                                                                 2023</A><FONT STYLE="color: blue">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465923128923/tm2333662d1_8k.htm">December&nbsp;26,
                                                                                                                                                                                                                 2023</A><FONT STYLE="color: blue">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465923130528/tm2333984d1_8k.htm">December&nbsp;29,
                                                                                                                                                                                                                 2023</A><FONT>, and </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465924001640/tm2333984d3_8k.htm" STYLE="-sec-extract: exhibit">January&nbsp;5,
                                                                                                                                                                                                                 2024</A> (as amended on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465924005246/tm243472d1_8ka.htm" STYLE="-sec-extract: exhibit">January 19, 2024</A>); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>the description of the Standard BioTools Common Stock contained in the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1162194/000119312511025057/d8a12b.htm">Form&nbsp;8-A</A>
                                                                                                                                                                                                                 relating thereto, filed with the SEC on February&nbsp;7, 2011, including any amendment or report filed for the purpose of updating
                                                                                                                                                                                                                 such description.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SEC file number for each of the documents
listed above is&nbsp;001-34180.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, all reports and other documents filed
by us pursuant to Section&nbsp;13(d), 13(c), 14 or 15(d)&nbsp;of the Exchange Act after the date of the registration statement of which
this prospectus is a part and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference
into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any statement contained in this prospectus or
in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that
is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded
will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You may request, orally or in writing, a copy
of any or all of the documents incorporated herein by reference. These documents will be provided to you at no cost, by contacting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Standard BioTools Inc.<BR>
2 Tower Place, Ste 2000<BR>
South San Francisco, California 94080<BR>
Attn: Investor Relations<BR>
(650) 266-6000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access these documents on our website, </FONT><I>http://www.standardbio.com</I>. The information contained on, or that can be
accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive
textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should rely only on information contained
in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information different from that
contained in this prospectus or incorporated by reference in this prospectus. We are not making offers to sell the securities in any jurisdiction
in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to
do so or to anyone to whom it is unlawful to make such offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm243480d1_s3img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Standard BioTools Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,837,152 SHARES OF COMMON STOCK<BR>
ISSUABLE UPON EXERCISE OF AWARDS<BR>
under the<BR>
SOMALOGIC, INC. 2009 EQUITY INCENTIVE PLAN<BR>
SOMALOGIC, INC. 2017 EQUITY INCENTIVE PLAN<BR>
SOMALOGIC, INC. 2021 OMNIBUS INCENTIVE PLAN<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED JUNE 6, 2014<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED NOVEMBER 19, 2018<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED SEPTEMBER 1, 2020<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED AUGUST 6, 2021<BR>
NON-STATUTORY STOCK OPTION AGREEMENT, DATED AUGUST 20, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>,
2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45pt"><B>Item 14.</B></TD><TD><B>Other Expenses of Issuance and Distribution</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The following table sets
forth estimated expenses in connection with the issuance and distribution of the securities being registered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount to be<BR>
 Paid</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left">SEC registration fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">8,979.29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Printing and engraving expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounting fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">*</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this
time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45pt"><B>Item 15.</B></TD><TD><B>Indemnification of Directors and Officers</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Section&nbsp;145 of the Delaware General Corporation
Law (the &ldquo;DGCL&rdquo;), permits a corporation to indemnify its directors and officers against expenses, including attorneys&rsquo;
fees, judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection with any action, suit or
proceeding brought by third parties. The directors or officers must have acted in good faith and in a manner they reasonably believed
to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reason
to believe their conduct was unlawful. In a derivative action, an action only by or in the right of the corporation, indemnification may
be made only for expenses, including attorney&rsquo;s fees, actually and reasonably incurred by directors and officers in connection with
the defense or settlement of an action or suit, and only with respect to a matter as to which they acted in good faith and in a manner
they reasonably believed to be in or not opposed to the best interests of the corporation. No indemnification shall be made if such person
shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which the action or suit was
brought determines upon application that the defendant officers or directors are fairly and reasonably entitled to indemnity for such
expenses despite such adjudication of liability. The Standard BioTools Charter provides that the registrant may indemnify its directors,
officers, employees or agents to the fullest extent permitted by applicable law and the Standard BioTools ByLaws provide that the registrant
shall indemnify its directors and officers to the fullest extent permitted by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Section&nbsp;102(b)(7)&nbsp;of the DGCL permits
a corporation to provide in its charter that a director or officer of the corporation shall not be personally liable to the corporation
or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability of (1)&nbsp;a director
or officer for any breach of the director&rsquo;s or officer&rsquo;s duty of loyalty to the corporation or its stockholders, (2)&nbsp;a
director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&nbsp;a
director for payments of unlawful dividends or unlawful stock purchases or redemptions, (4)&nbsp;a director or officer for any transaction
from which the director or officer derived an improper personal benefit, or (5)&nbsp;an officer in any action by or in the right of the
corporation. The Standard BioTools Charter provides for such limitation of liability with respect to directors of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Standard BioTools has entered into indemnification
agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification
for related expenses including, among others, attorneys&rsquo; fees, judgments, fines and settlement amounts incurred by any of these
individuals in any action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The indemnification rights set forth above shall
not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, the Standard BioTools
Charter, the Standard BioTools Bylaws, any agreement, any vote of stockholders or disinterested directors or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Standard BioTools maintains standard policies
of insurance that provide coverage (1)&nbsp;to its directors and officers against loss rising from claims made by reason of breach of
duty or other wrongful act and (2)&nbsp;to Standard BioTools with respect to indemnification payments that it may make to such directors
and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45pt"><B>Item 16.</B></TD><TD><B>Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exhibits to this registration statement are listed in the Exhibit&nbsp;Index immediately prior the signature page&nbsp;hereto, which Exhibit&nbsp;Index
is hereby </FONT>incorporated by reference into this Item 16 by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45pt"><B>Item 17.</B></TD><TD><B>Undertakings</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>To include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth
in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule&nbsp;424(b)&nbsp;if,
in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth
in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Provided,
however</I></FONT>, that paragraphs (a)(1)(i), (a)(1)(ii)&nbsp;and (a)(1)(iii)&nbsp;of this section do not apply if the information required
to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and
Exchange Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of the Exchange Act, that are incorporated
by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;that is part
of the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(5)</TD><TD>That, for the purpose of determining liability under the Securities Act to any purchaser:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD>Each prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3)&nbsp;shall be deemed to be part of the registration statement
as of the date the filed prospectus was deemed part of and included in the registration statement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD>Each prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7)&nbsp;as part of a registration statement in
reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing
the information required by Section&nbsp;10(a)&nbsp;of the Securities Act shall be deemed to be part of and included in the registration
statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of
sale of securities in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and
any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating
to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(6)</TD><TD>That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD>Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD>The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD>Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
registrant&rsquo;s annual report pursuant to Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the Exchange Act (and, where applicable,
each filing of an employee benefit plan&rsquo;s annual report pursuant to Section&nbsp;15(d)&nbsp;of the Exchange Act) that is incorporated
by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 6%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No.</B></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 46%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed<BR>
 Herewith</B></FONT></TD>
    <TD STYLE="width: 7%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File No.</B></FONT></TD>
    <TD STYLE="width: 9%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated<BR>
 by Reference<BR>
 From <BR>
Exhibit&nbsp;<BR>
Number</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date Filed</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000110465923106606/tm2327474d1_ex2-1.htm">Agreement and Plan of Merger, dated as of October&nbsp;4, 2023, by and among Standard BioTools Inc., SomaLogic,&nbsp;Inc. and Martis Merger Sub Inc.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/4/2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312511078412/dex31.htm">Eighth Amended and Restated Certificate of Incorporation</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/28/2011</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312522093794/d300506dex48.htm">Amended and Restated Bylaws</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-264086</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312522093794/d300506dex43.htm">Certificate of Amendment to Eighth Amended and Restated Certificate of Incorporation, filed April&nbsp;1, 2022</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-264086</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/tm2333984d3_ex3-1.htm">Second Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation filed on January&nbsp;4, 2024</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/5/2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312522093794/d300506dex41.htm">Specimen Common Stock Certificate of the Registrant</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-264086</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312516774501/d294669dex31.htm">Certificate of Designation of Rights, Preferences and Privileges of Series&nbsp;A Participating Preferred Stock</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2016</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000114420417039703/v471897_ex3-1.htm">Certificate of Elimination of Series&nbsp;A Participating Preferred Stock of the Registrant</A></FONT>.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/2/2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/d314141dex36.htm">Certificate of Designations of Rights, Preferences and Privileges of Series&nbsp;B-1 Convertible Preferred Stock</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/5/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/d314141dex37.htm">Certificate of Designations of Rights, Preferences and Privileges of Series&nbsp;B-2 Convertible Preferred Stock</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/5/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000110465919066659/tm1923592d1_ex4-1.htm">Indenture, dated November&nbsp;22, 2019, by and between Fluidigm Corporation and U.S. Bank National Association</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2019</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000110465919066659/tm1923592d1_ex4-1.htm">Form&nbsp;of
5.25% Convertible Senior Note due 2024</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2019</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312522036985/d307863dex101.htm">Series&nbsp;B-1 Loan Agreement, dated as of January&nbsp;23, 2022, by and among Fluidigm Corporation, Casdin Partners Master Fund, L.P., and Casdin Private Growth Equity Fund&nbsp;II, L.P</A>.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 7%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1162194/000119312522016151/d243622dex102.htm">Series&nbsp;B-2 Loan Agreement, dated as of January&nbsp;23, 2022, by and among Fluidigm Corporation, Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP</A>.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-34180</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/24/2022</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex23-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of PricewaterhouseCoopers LLP,&nbsp;Independent Registered Public Accounting Firm.</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex23-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex23-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ernst&nbsp;&amp; Young LLP,&nbsp;Independent Registered Public Accounting Firm.</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex23-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included as part of Exhibit&nbsp;5.1 hereto).</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sig_001">Power of Attorney (included on the signature page&nbsp;to this registration statement).</A></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#sig_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1#</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837412/000121390021026384/fs42021ex10-7_cmlifesci2.htm">SomaLogic,&nbsp;Inc. 2009 Equity Incentive Plan</A></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4/A</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-256127</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/5/2021</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2#</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837412/000121390021026384/fs42021ex10-10_cmlifesci2.htm">SomaLogic,&nbsp;Inc. 2017 Equity Incentive Plan</A></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4/A</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-256127</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/5/2021</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3#</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1837412/000121390021040546/fs42021a3_cmlifesci2.htm#T004">SomaLogic,&nbsp;Inc. 2021 Omnibus Incentive Plan</A></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4/A</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-256127</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/5/2021</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4#</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex99-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of 2014 Non-Statutory Stock Option Agreement.</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex99-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5#</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex99-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Non-Statutory Stock Option Agreement.</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex99-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex-filingfees.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table.</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm243480d1_ex-filingfees.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
</FONT>&dagger;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The schedules and exhibits to this exhibit have been omitted pursuant to Item&nbsp;601(b)(2)&nbsp;of
Regulation&nbsp;S-K.<BR>
#&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indicates management contract or compensatory plan, contract, or arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="sig_001"></A>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&nbsp;S-3
and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
of South San Francisco, State of California, on January 19, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">STANDARD BIOTOOLS INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Michael Egholm, Ph.D.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Michael Egholm, Ph.D.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
the undersigned officers and directors of Standard BioTools Inc., hereby severally constitute and appoint Michael Egholm, Ph.D. and Jeffrey
Black and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full
power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities,
to sign any and all amendments (including, without limitation, post-effective amendments) to this registration statement (or any other
registration statement for the same offering that is to be effective upon filing pursuant to Rule&nbsp;462(b)&nbsp;under the Securities
Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every
act and thing requisite or necessary to be done in and about the premises, as fully to all intents and </FONT>purposes as he or she might
or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her
substitute or substitutes may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the </FONT>Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White; width: 33%; text-align: center; padding-bottom: 1pt"><U>Signature</U></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; width: 1%; padding-bottom: 1pt"></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; width: 33%; padding-bottom: 1pt"><U>Title</U></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; background-color: White; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White; width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Date</U></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; background-color: White; font-size: 10pt; text-align: left">/s/ Michael Egholm, Ph.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt; text-align: left">Michael Egholm</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">President, Chief Executive Officer
    and Director (Principal Executive Officer)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                                                                                               19, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; background-color: White; font-size: 10pt; text-align: left">/s/ Jeffrey Black</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Chief Financial Officer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Jeffrey
    Black</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">(Principal Financial and Accounting
    Officer)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                                                                                               19, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">/s/ Tom Carey</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Chairman of the Board of Directors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Tom Carey</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                                                                                               19, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">/s/ Frank
    Witney, Ph.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Frank
    Witney, Ph.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                                                                                               19, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">/s/ Fenel
    M. Eloi</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Fenel
    M. Eloi</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                                                                                               19, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">/s/ Troy
    Cox</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Troy
    Cox</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
19, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">/s/ Eli Casdin</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Eli Casdin</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                                                                                               19, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">/s/ Kathy
    Hibbs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">Kathy
    Hibbs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
                                                                                                               19, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm243480d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><IMG SRC="image_006.jpg" ALT="" STYLE="height: 117px; width: 95px">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt; width: 40%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>One
    Financial Center</B></FONT>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Boston,
                                            MA 02111</B></P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>617
                                            542 6000</B></FONT></P>
                                                                                <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>mintz.com</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January&nbsp;19, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Standard BioTools Inc.<BR>
2 Tower Place, Suite&nbsp;2000<BR>
South San Francisco, CA 94080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Re:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Statement
on Form&nbsp;S-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have acted as legal counsel to Standard BioTools Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the preparation
and filing with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) of a Registration Statement on Form&nbsp;S-3 (the
 &ldquo;Registration Statement&rdquo;), pursuant to which the Company is registering the issuance under the Securities Act of 1933, as
amended (the &ldquo;Securities Act&rdquo;), of an aggregate of 10,837,152 shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s common
stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;), that may be issued pursuant to the exercise of options to purchase shares
of Common Stock pursuant to the SomaLogic,&nbsp;Inc. 2009 Equity Incentive Plan, the SomaLogic,&nbsp;Inc. 2017 Equity Incentive Plan
and the SomaLogic,&nbsp;Inc. 2021 Omnibus Incentive Plan (collectively, the &ldquo;SomaLogic Equity Plans&rdquo;), <FONT STYLE="background-color: white">as
well as pursuant to that certain Non-Statutory Stock Option Agreement, dated June&nbsp;6, 2014, Non-Statutory Stock Option Agreement,
dated November&nbsp;19, 2018, Non-Statutory Stock Option Agreement, dated September&nbsp;1, 2020, Non-Statutory Stock Option Agreement,
dated August&nbsp;6, 2021 and Non-Statutory Stock Option Agreement, dated August&nbsp;20, 2021 (collectively, the &ldquo;Non-Statutory
Stock Option Agreements&rdquo;)</FONT>. Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October&nbsp;4,
2023 (the &ldquo;Merger Agreement&rdquo;), by and among the Company, Martis Merger Sub,&nbsp;Inc., a Delaware corporation and wholly
owned subsidiary of the Company (&ldquo;Merger Sub&rdquo;), and SomaLogic,&nbsp;Inc., a Delaware corporation (&ldquo;SomaLogic&rdquo;),
each outstanding option to purchase shares of common stock, par value $0.0001 per share, of SomaLogic, whether vested or unvested, held
by former SomaLogic employees, directors and consultants under the SomaLogic Equity Plans and Non-Statutory Stock Option Agreements,
was assumed and converted into options to purchase shares of the Company&rsquo;s Common Stock. This opinion is being rendered in connection
with the filing of the Registration Statement with the Commission. All capitalized terms used herein and not otherwise defined shall
have the respective meanings given to them in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with this opinion, we have examined the Company&rsquo;s Eighth Amended and Restated Certificate of Incorporation, as amended,
and Amended and Restated Bylaws, each as currently in effect; such other records of the corporate proceedings of the Company and certificates
of the Company&rsquo;s officers as we have deemed relevant; and the Registration Statement and the exhibits thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents
submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the
originals of such copies, and the truth and correctness of any representations and warranties contained therein. In addition, we have
assumed that the Company will receive any required consideration in accordance with the terms of the SomaLogic Equity Plans and Non-Statutory
Stock Option Agreements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="background-color: White">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase; background-color: White">Boston&nbsp;&nbsp;&nbsp;&nbsp;Los
Angeles&nbsp;&nbsp;&nbsp;&nbsp;MIAMI&nbsp;&nbsp;&nbsp;&nbsp;New York&nbsp;&nbsp;&nbsp;&nbsp;San Diego&nbsp;&nbsp;&nbsp;&nbsp;San Francisco&nbsp;&nbsp;&nbsp;&nbsp;toronto&nbsp;&nbsp;&nbsp;&nbsp;Washington</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: White">Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; padding-right: 5.4pt; padding-left: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>MINTZ</B></FONT></TD>
    <TD ROWSPAN="4" STYLE="width: 47%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font-size: 10pt"><IMG SRC="tm243480d1_ex5-1img02.jpg" ALT="">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">January&nbsp;19,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Page&nbsp;2</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
opinion expressed herein is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to
the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities
or blue sky laws of any state or any foreign jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Please
note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.
This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to
advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or
opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
upon the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the SomaLogic Equity
Plans and Non-Statutory Stock Option Agreements, as applicable, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
hereby consent to the filing of this opinion letter as Exhibit&nbsp;5.1 to the Registration Statement and to the use of our name under
the caption &ldquo;Legal Matters&rdquo; in the Registration Statement and in the Prospectus forming a part thereof and any supplement
thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section&nbsp;7
of the Securities Act or the rules&nbsp;and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt; width: 50%"></TD>
  <TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%">Very truly yours,</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt">&nbsp;</TD>
  <TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt"></TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0in; text-indent: -0.01pt">/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
  P.C.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -0.01pt"></TD>
  <TD STYLE="padding-left: 0in; text-indent: -0.01pt">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm243480d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in this Registration
Statement on Form S-3 of Standard BioTools Inc. of our report dated March 14, 2023 relating to the financial statements and the effectiveness
of internal control over financial reporting, which appears in Standard BioTools Inc.&rsquo;s Annual Report on Form 10-K for the year
ended December 31, 2022. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Jose, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 19, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>tm243480d1_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the reference to our firm under the caption &quot;Experts&quot;
in the Registration Statement (Form S-3) and related Prospectus of Standard BioTools Inc. for the registration of 10,837,152 shares of
its common stock issuable upon exercise of awards under the SomaLogic, Inc. 2009 and 2017 Equity Incentive Plans, the SomaLogic, Inc.
2021 Omnibus Incentive Plan, and the Non-Statutory Stock Option Agreements dated June 6, 2014, November 19, 2018, September 1, 2020, August
6, 2021 and August 20, 2021, and to the incorporation by reference of our report dated March 28, 2023, with respect to the consolidated
financial statements of SomaLogic, Inc. as of and for the years ended December 31, 2022 and 2021 included in the Amendment No. 1 to the
Current Report on Form 8-K of Standard BioTools Inc., filed with the Securities and Exchange Commission on January 19, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst &amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Denver, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 19, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>tm243480d1_ex99-4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SOMALOGIC,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Non-Statutory Stock Option Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SomaLogic,&nbsp;Inc. (the
 &ldquo;Company&rdquo;) hereby grants an Option to purchase shares of the Company&rsquo;s common stock to you, the Optionee named below.
This Option is being granted outside of the Company&rsquo;s 2009 Equity Incentive Plan (the &ldquo;Plan&rdquo;), but this Agreement will
incorporate provisions of the Plan by reference. In addition, capitalized terms that are not defined in this Agreement shall have the
meaning set forth in the Plan as it currently exists or as it is amended in the future. The terms and conditions of the Option Award
are set forth in this Agreement, consisting of this cover page&nbsp;and the Option Terms and Conditions on the following pages, and in
the Plan document which is attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; border: Black 1pt solid; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Optionee:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ref.
    No.:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.&nbsp;of
    Shares Covered:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    of Grant:&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price Per Share:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    Date:&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, you agree
to all of the terms and conditions contained in this Agreement and in the Plan document, a copy of which is attached. You acknowledge
that you have reviewed these documents and that they set forth the entire agreement between you and the Company regarding your right
to purchase shares of the Company&rsquo;s common stock pursuant to this Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 48%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPTIONEE:</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD><TD STYLE="text-align: justify; width: 48%">SOMALOGIC,&nbsp;INC.:</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SomaLogic,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Non-Statutory Stock Option Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Option Terms and Conditions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify"><B><U>Non-Qualified
                                            Stock Option</U></B>. This Option is not intended to be an &ldquo;incentive stock option&rdquo;
                                            within the meaning of Section&nbsp;422 of the Internal Revenue Code and will be interpreted
                                            accordingly.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: justify"><B><U>Vesting
                                            and Exercise Schedule</U></B>. This Option is fully vested and exercisable as of its date
                                            of grant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: justify"><B><U>Expiration</U></B>.
                                            This Option will expire and will no longer be exercisable at 5:00 p.m.&nbsp;Mountain Time
                                            on the earliest of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">The
                                            expiration date specified on the cover page&nbsp;of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">One
                                            year following your death; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">The
                                            date (if any) fixed for termination or surrender of Options pursuant to Sections 12(b)(2),
                                            (b)(3), (c)&nbsp;or (d)&nbsp;of the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: justify"><B><U>Exercise
                                            of Option</U></B>. This Option may be exercised at any time during the Option term by delivering
                                            a written notice of exercise to the Company at its principal executive office, and by providing
                                            for payment of the exercise price of the Shares being acquired. The notice of exercise, in
                                            the form attached to this Agreement, shall be provided to the Company&rsquo;s Chief Financial
                                            Officer. The notice shall state the number of Shares to be purchased, and shall be signed
                                            by the person exercising the Option. If you are not the person exercising the Option, the
                                            person submitting the notice must also must submit appropriate proof of his/her right to
                                            exercise the Option.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD STYLE="text-align: justify"><B><U>Payment
                                            of Exercise Price</U></B>. When you submit your notice of exercise, you must include payment
                                            of the exercise price of the Shares being purchased through one or a combination of the following
                                            methods:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Cash
                                            (including personal check, cashier&rsquo;s check or money order);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">By
                                            delivery to the Company of Shares (by actual delivery or attestation of ownership in a form
                                            approved by the Company) already owned by you that are not subject to any security interest
                                            and that have an aggregate Fair Market Value on the date of exercise equal to the exercise
                                            price of the Shares being purchased; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">By
                                            authorizing the Company to retain, from the total number of Shares as to which the Option
                                            is being exercised, that number of Shares having a Fair Market Value on the date of exercise
                                            equal to the exercise price for the total number of Shares as to which the Option is being
                                            exercised.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">However, if the Committee determines,
m any given circumstance, that payment of the exercise price with Shares or by authorizing the Company to retain Shares is undesirable
for any reason, you will not be permitted to pay any portion of the exercise price in that manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT></TD><TD STYLE="text-align: justify"><B><U>Delivery
                                            of Certificate</U></B>. As soon as practicable after the Company receives the notice and
                                            exercise price provided for above, and determined that all conditions to exercise, including
                                            Section&nbsp;7 of this Agreement, have been satisfied, it shall deliver to the person exercising
                                            the Option, in the name of such person, a certificate or certificates representing the Shares
                                            being purchased. The Company shall pay any original issue or transfer taxes with respect
                                            to the issue or transfer of the Shares and all fees and expenses incurred by it in connection
                                            therewith. All Shares so issued shall be fully paid and nonassessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.</FONT></TD><TD STYLE="text-align: justify"><B><U>Compliance
                                            with Laws</U></B>. This Option may be exercised only if the issuance of Shares upon such
                                            exercise complies with all applicable legal requirements, including compliance with the provisions
                                            of applicable federal and state securities laws. If the sale of Shares upon the exercise
                                            of this Option is not registered under the Securities Act of 1933, as amended (the &ldquo;Securities
                                            Act&rdquo;), you shall acknowledge at the time of exercise that (i)&nbsp;the Shares you are
                                            acquiring are deemed &ldquo;restricted securities&rdquo; for purposes of Rule&nbsp;144 under
                                            the Securities Act, and you are acquiring the Shares for investment purposes and not with
                                            a view to the resale or distribution of such Shares, and (ii)&nbsp;the Shares you are acquiring
                                            may not be sold, pledged or otherwise transferred without (A)&nbsp;an effective registration
                                            or qualification thereof under the Securities Act and the securities laws of any applicable
                                            state or other jurisdiction, or (B)&nbsp;evidence, which may include an opinion of counsel,
                                            satisfactory to the Company and its counsel that such registration and qualification is not
                                            required.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.</FONT></TD><TD STYLE="text-align: justify"><B><U>Transfer
                                            of Option</U></B>. During your lifetime, only you (or your guardian or legal representative
                                            in the event of legal incapacity) may exercise this Option except in the case of a transfer
                                            described below. You may not assign or transfer this Option except (i)&nbsp;for a transfer
                                            upon your death in accordance with your will, by the laws of descent and distribution or
                                            pursuant to a beneficiary designation submitted in accordance with Section&nbsp;6(d)&nbsp;of
                                            the Plan, (ii)&nbsp;pursuant to a qualified domestic relations order, or (iii)&nbsp;with
                                            the prior written approval of the Company, by gift, in a form accepted by the Company. The
                                            Option held by any such transferee will continue to be subject to the same terms and conditions
                                            that were applicable to the Option immediately prior to its transfer and may be exercised
                                            by such transferee as and to the extent that the Option has become exercisable and has not
                                            terminated in accordance with the provisions of the Plan and this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.</FONT></TD><TD STYLE="text-align: justify"><B><U>No
                                            Stockholder Rights Before Exercise</U></B>. Neither you nor any permitted transferee of this
                                            Option will have any of the rights of a stockholder of the Company with respect to any Shares
                                            subject to this Option until a certificate evidencing such Shares has been issued (or an
                                            appropriate book entry in the Company&rsquo;s stock register has been made). No adjustments
                                            shall be made for dividends or other rights if the applicable record date occurs before your
                                            stock certificate has been issued (or an appropriate book entry has been made), except as
                                            otherwise described in the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.</FONT></TD><TD STYLE="text-align: justify"><B><U>Governing
                                            Plan Document</U></B>. This Agreement and Option are subject to all the provisions of the
                                            Plan to the same extent as if the Option had been granted under the Plan, and to all interpretations,
                                            rules&nbsp;and regulations which may, from time to time, be adopted and promulgated by the
                                            Committee pursuant to the Plan. If there is any conflict between the provisions of this Agreement
                                            and the Plan, the provisions of the Plan will govern.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.</FONT></TD><TD STYLE="text-align: justify"><B><U>Choice
                                            of Law</U></B>. This Agreement will be interpreted and enforced under the laws of the State
                                            of Delaware (without regard to its conflicts or choice of law principles).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.</FONT></TD><TD STYLE="text-align: justify"><B><U>Binding
                                            Effect</U></B>. This Agreement will be binding in all respects on your heirs, representatives,
                                            successors and assigns, and on the successors and assigns of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.</FONT></TD><TD STYLE="text-align: justify"><B><U>Other
                                            Agreements</U></B>. You agree that in connection with the exercise of this Option, you will
                                            execute such documents as may be necessary to become a party to any stockholder, voting or
                                            similar agreements as the Company may require.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.</FONT></TD><TD STYLE="text-align: justify"><B><U>Restrictive
                                            Legends</U></B>. The Company may place a legend or legends on any certificate representing
                                            Shares issued upon the exercise of this Option summarizing transfer and other restrictions
                                            to which the Shares may be subject under applicable securities laws, other provisions of
                                            this Agreement, or other agreements contemplated by Section&nbsp;13 of this Agreement. You
                                            agree that in order to ensure compliance with the restrictions referred to in this Agreement,
                                            the Company may issue appropriate &ldquo;stop transfer&rdquo; instructions to its transfer
                                            agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.</FONT></TD><TD STYLE="text-align: justify"><B><U>Market
                                            Standoff Agreement</U></B>. In connection with any underwritten public offering by the Company
                                            of its equity securities, including the initial public offering of the Company&rsquo;s securities,
                                            and upon request of the Company or the underwriters managing such underwritten offering,
                                            you agree not to sell, make any short sale of, loan, hypothecate, pledge, grant any option
                                            for the purchase of, or otherwise dispose of or transfer for value any securities of the
                                            Company (other than those included in the registration) without the prior written consent
                                            of the Company or such underwriters, as the case may be, for such period of time (not to
                                            exceed 180 days) after the effective date of such registration as may be requested by the
                                            Company or such managing underwriters, and to execute an agreement reflecting the foregoing
                                            as may be requested by the underwriters at the time of such public offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.</FONT></TD><TD STYLE="text-align: justify"><B><U>Right
                                            of First Refusal</U></B>. Shares that you acquire upon exercise of this Option are subject
                                            to the right of first refusal on the part of the Company that is described in this Section&nbsp;16
                                            until such time as the Company&rsquo;s Stock is registered under Section&nbsp;12 of the Securities
                                            Exchange Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Before
                                            any Shares acquired upon the exercise of this Option may be transferred in any manner, including
                                            by sale, pledge or other encumbrance, you must first deliver a written notice (a &ldquo;Transfer
                                            Notice&rdquo;) to the Company stating (i)&nbsp;that you desire to transfer such Shares and
                                            (ii)&nbsp;the price and other material terms and conditions of the proposed transfer. The
                                            Transfer Notice shall be accompanied by a certificate from you certifying that you have received
                                            a written offer from a third party financially capable of carrying out the terms of the offer
                                            to acquire the Shares at the price and terms set forth in the Transfer Notice, and identifying
                                            such third party, including the name and address. Any notice that does not contain all information
                                            required by this Section&nbsp;16(a)&nbsp;shall not be considered a Transfer Notice for purposes
                                            of this Agreement. The Transfer Notice shall be deemed a legally enforceable offer by you
                                            to sell the Shares to which the Transfer Notice refers to the Company pursuant to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">Within
                                            30 days after receipt of a Transfer Notice (the &ldquo;Company Period&rdquo;), the Company
                                            may elect, by delivering to you a written notice (a &ldquo;Company Notice&rdquo;) of its
                                            election to purchase all or any part (provided that it is a whole number) of the Shares to
                                            which the Transfer Notice refers, on the same terms and conditions specified in the Transfer
                                            Notice (or on economically equivalent terms and conditions specified in the Company Notice).
                                            If the Company does not elect to purchase any of the Shares, the Company shall send a notice
                                            to such effect you prior to the end of the Company Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">If
                                            a dispute arises between you and the Company concerning the economically equivalent terms
                                            and conditions specified in a Company Notice, the determination of the economic equivalence
                                            of such terms and conditions shall be made by an independent investment banking firm selected
                                            by the Company and consented to by you, which consent shall not be unreasonably withheld.
                                            You and the Company shall cooperate fully in assisting any such investment banking firm in
                                            making its determination, and such determination shall be made no later than 75 days after
                                            the date that the Company received the Transfer Notice. The Company shall bear the cost of
                                            such investment banking firm. I f the investment banking firm takes more than 75 days to
                                            make its determination, the period of time after the 75 days shall be added to the Company&rsquo;s
                                            time limit for consummating the transaction as required by Section&nbsp;16(d)&nbsp;of this
                                            Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify">If
                                            the Company elects to acquire your Shares pursuant to this Section&nbsp;16, you and the Company
                                            shall consummate the sale and purchase of such Shares no later than 90 days after the date
                                            that the Company received the Transfer Notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify">To
                                            the extent the Company does not exercise its rights under this Section&nbsp;16 within the
                                            specified time periods, you may, subject to Section&nbsp;7 of this Agreement, transfer the
                                            Shares specified in your Transfer Notice to the third party specified in such Transfer Notice
                                            at the price and on the terms specified in such notice, so long as such transfer is consummated
                                            within 120 days after the date that the Company received the Transfer Notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT></TD><TD STYLE="text-align: justify">You
                                            hereby acknowledge that the right of the Company to purchase your Shares in the manner described
                                            in this Section&nbsp;16 is not unreasonable under the circumstances existing as of the date
                                            you execute this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>By signing the cover page&nbsp;of this
Agreement, you agree to all the terms and conditions described above and in the Plan document.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Non-Statutory Stock Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">_______________, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SomaLogic,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2945 Wilderness Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Boulder, Colorado 80301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby exercise the following option&rsquo;
(the &ldquo;Option&rdquo;) granted to me outside of the SomaLogic,&nbsp;Inc. 2009 Equity Incentive Plan (as amended from time to time,
the &ldquo;Plan&rdquo;) with respect to the number of shares of common stock of SomaLogic,&nbsp;Inc. (the &ldquo;Company&rdquo;) indicated
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 59%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date of Grant of Option:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Exercise Price Per Share:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Number of Shares With Respect to Which&#8239;the
    Option is Hereby Exercised:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Total Exercise Price:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Enclosed with this Notice is
                                            a check, cashier&rsquo;s check or money order in the amount of the Total Exercise Price.</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Enclosed
                                            with this Notice is a certificate evidencing unencumbered Shares (duly endorsed in blank)
                                            having an aggregate Fair Market Value (as defined in the Plan) equal to or in excess of the
                                            Total Exercise Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">I
                                            elect to pay the Total Exercise Price through a reduction in the number of Shares to be delivered
                                            to me upon this exercise of the Option.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this exercise,&nbsp;I represent,
warrant and acknowledge as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 2pt; width: 0.25in"></TD><TD STYLE="padding-bottom: 2pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: justify">I
                                            am an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)&nbsp;of Regulation
                                            D promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 2pt; width: 0.25in"></TD><TD STYLE="padding-bottom: 2pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: justify">I
                                            am acquiring the Shares as a result of this Option exercise for my own account, and acknowledge
                                            that the Shares have not been registered under the Securities Act and are deemed to constitute
                                            &ldquo;restricted securities&rdquo; under Rule&nbsp;144 of the Securities Act. I have no
                                            present intention of distributing or selling such Shares, and will transfer them only as
                                            permitted under applicable federal and state securities laws.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">I
                                            am the owner of all Shares delivered with this Notice free and clear of all liens, security
                                            interests and other restrictions or encumbrances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please issue a certificate (the &ldquo;Certificate&rdquo;)
for the number of Shares with respect to which the Option is being exercised (or the net number of Shares if the Total Exercise Price
is being paid through a reduction in the number of Shares to be delivered to me) in the name of the person indicated below and deliver
the Certificate to the address indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-size: 10pt">Name in Which to Issue Certificate:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 59%"><FONT STYLE="font-size: 10pt">&nbsp; </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Address to Which Certificate Should be Delivered:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Principal Mailing Address for Holder of the
    Certificate (if different from&#8239;above):</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4.8in"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name, please print</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Social Security Number</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGULATION D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACCREDITED INVESTOR QUALIFICATION QUESTIONNAIRE
(INDIVIDUAL)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Questionnaire is being distributed to you
in connection with your receipt of an option (the &ldquo;<B><I>Option</I></B>&rdquo;) to purchase shares of Common Stock of SomaLogic,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;). The purpose of this Questionnaire is to assure the Company that the
grant of the Option will meet the standards imposed by the Securities Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;),
and applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Your answers will be kept confidential. However,
by signing this Questionnaire you agree that the Company and its counsel may rely on the information set forth in this Questionnaire
for purposes of complying with all applicable securities laws and may present this Questionnaire to such parties as it reasonably deems
appropriate if called upon to establish its compliance with such securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
complete, sign, date and return one copy of this Questionnaire to the Company&rsquo;s legal counsel,</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">at</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">.
If the answer to a question is &ldquo;none&rdquo; or &ldquo;not applicable,&rdquo; please so state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Residence
                                            Information</B></FONT>. Please provide your full legal name, residence address, phone and
                                            fax numbers, e-mail address and social security number.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                                    </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Personal
                                            Information</B></FONT>. Please indicate the state that issued your driver&rsquo;s license
                                            and the state in which you are registered to vote.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">3.</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">My Income.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Do you reasonably expect
either your income<SUP>1</SUP> from all sources during this year to exceed $200,000 or, if you are married, the joint income of you and
your spouse from all sources during this year to exceed $300,000?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;Yes</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>For purposes of this Questionnaire, &ldquo;<B><I>income</I></B>&rdquo; means adjusted gross income, as reported for federal
income tax purposes, increased by the following amounts: (a) the amount of any tax exempt interest income received, (b) the amount of
losses claimed as a limited partner in a limited partnership, (c) any deduction claimed for depletion, (d) amounts contributed to an
IRA or Keogh retirement plan, (e) alimony paid, and (f) any amounts by which income from long-term capital gains has been reduced in
arriving at adjusted gross income pursuant to the provisions of Section 1202 of the Internal Revenue Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3in"><FONT STYLE="font-size: 10pt">If no, please specify amount of expected
    income:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Was your yearly individual
income from all sources during each of the last two years in excess of $200,000 or, if you are married, was the joint income of you and
your spouse during each of those years in excess of $300,000?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;Yes</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5.3in"><FONT STYLE="font-size: 10pt">If no, please specify amount of
    your total individual and/or joint income in the last two years:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">4.</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">My Net Worth.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Is your net worth,<SUP>2
</SUP>including the net worth of your spouse, in excess of $1,000,000 (excluding the value of your primary residence)? Please remember
that your net worth for this question should include the value of any other shares of stock or options held by you and your spouse and
any personal property owned by you or your spouse (<I>e.g.</I> furniture, jewelry, other valuables,&nbsp;etc.), but must exclude the
value of your primary residence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;Yes</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2.2in">If no, please specify your net worth:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned represents
that the information contained herein is complete and accurate and may be relied upon by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>In
Witness Whereof</B></FONT><FONT STYLE="font-size: 10pt">, the undersigned has executed this Accredited Investor Qualification Questionnaire
on</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(Signature)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(Printed Name)</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT>For purposes of Question 4, &ldquo;<B><I>net worth</I></B>&rdquo; means the excess of total assets, excluding your primary
residence, at fair market value over total liabilities, including (a) your mortgage or any other liability secured by your primary residence
only if and to the extent that it exceeds the value of your primary residence and (b) any incremental debt secured (or to be secured)
by your primary residence if such debt was incurred (or will be incurred) in the sixty (60) days prior to the grant of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>6
<FILENAME>tm243480d1_ex99-5.htm
<DESCRIPTION>EXHIBIT 99.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SOMALOGIC,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Non-Statutory Stock Option Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SomaLogic,&nbsp;Inc. (the
 &ldquo;Company&rdquo;) hereby grants to you, the Optionee named below, a Stock Option to purchase shares of the Company&rsquo;s Class&nbsp;B
common stock, par value $.01 per share, (the &ldquo;Option&rdquo;), pursuant to the terms and conditions of this Non-Statutory Stock
Option Agreement, consisting of this cover page&nbsp;and the Option Terms and Conditions on the following pages&nbsp;(this &ldquo;Agreement&rdquo;).
Capitalized terms used in this Agreement have the meanings ascribed to them in Exhibit&nbsp;A attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 5.4pt; width: 50%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name
    of Optionee: </FONT></TD>
    <TD STYLE="padding-bottom: 5.4pt; width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Grant
    number:&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">No.&nbsp;
    of Shares Covered:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Date
    of Grant:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Exercise
    Price Per Share:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Expiration
    Date:&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vesting and Exercise Schedule:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Dates</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Early Exercise is not permitted.</P></TD>
    <TD STYLE="padding-bottom: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Portion of Shares as to Which Option <U>Becomes
    Vested and Exercisable</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, you agree
to all of the terms and conditions contained in this Agreement. You acknowledge that you have reviewed these documents and that they
set forth the entire agreement between you and the Company regarding your right to purchase shares of the Company&rsquo;s Class&nbsp;B
common stock, par value $0.01 per share, pursuant to the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>OPTIONEE:</TD>
    <TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">SOMALOGIC,&nbsp;INC.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                               <TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; width: 48%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD><TD STYLE="text-align: justify; width: 3%">By:</TD>
                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
                                                                                                               </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SomaLogic,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Non-Statutory Stock Option Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Option Terms and Conditions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Administration</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendments</U>.
The Committee may unilaterally amend the terms of the Option, except that no such amendment may materially impair your rights under the
Option without your consent, unless such amendment is necessary to comply with applicable law, stock exchange rules&nbsp;or accounting
rules. The Committee shall have the authority, in its discretion, to take such actions as it deems necessary or advisable to administer
the Option, including accelerating the vesting or extending the exercise period of the Option, or otherwise amending these Option Terms
and Conditions, subject to the requirements of this Section; and interpreting this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acts
of the Committee; Delegation</U>. A majority of the members of the Committee shall constitute a quorum for any meeting of the Committee,
and any act of a majority of the members present at any meeting at which a quorum is present or any act unanimously approved in writing
by all members of the Committee shall be the act of the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Finality
of Decisions</U>. The Committee&rsquo;s interpretation of the Option and all related decisions or resolutions of the Board or Committee
shall be final and binding on all parties with an interest therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Non-Qualified
Stock Option</U></B>. The Option is a Non-Statutory Stock Option and is not intended to be an Incentive Stock Option and will be interpreted
accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>General
Terms</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares</U>. Unless otherwise determined by the Committee, the number of Shares subject to the Option shall always be a whole
number. No fractional Shares may be issued under the Option, but the Committee may, in its discretion, pay cash in lieu of any fractional
Share in settlement of the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
Except as provided in this Section&nbsp;3(b), (i)&nbsp;during your lifetime, only you or your guardian or legal representative may exercise
the Option, or receive payment with respect to the Option; and (ii)&nbsp;the Option may not be sold, assigned, transferred, exchanged
or encumbered other than by will or the laws of descent and distribution. Any attempted transfer in violation of this Section&nbsp;3(b)&nbsp;shall
be of no effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Designation
of Beneficiary</U>. You may designate a beneficiary or beneficiaries to exercise the Option or receive a payment under the Option payable
on or after your death. Any such designation shall be on a form approved by the Committee and shall be effective upon its receipt by
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination
of Service</U>. If your Service with the Company and its Affiliates terminates, the following provisions shall apply (in all cases subject
to the scheduled expiration of the Option):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
termination of Service for Cause, all unexercised portions of the Option shall be immediately forfeited without consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
termination of Service for any other reason, all unvested and unexercisable portions of the Option shall be immediately forfeited without
consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
termination of Service for any reason other than Cause, your Disability or your death, the currently vested and exercisable portions
of the Option may be exercised for a period of three (3)&nbsp;months after the date of such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(4)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
termination of Service due to your Disability, the currently vested and exercisable portions of the Option may be exercised for a period
of twelve (12) months after the date of such termination (except as otherwise provided in Section&nbsp;3(d)(5)&nbsp;below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(5)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">After
your death, if you die either during your Service with the Company or within three (3)&nbsp;months after your Service terminates for
any reason other than Cause, the currently vested and exercisable portions of the Option may be exercised for a period of eighteen (18)
months thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Employment or Other Service Rights</U>. Nothing in this Agreement will confer upon you any right to continue to serve the Company or
an Affiliate in your capacity in effect at the time the Option is granted or will affect the right of the Company or an Affiliate to
terminate (i)&nbsp;the employment of an Employee with or without notice and with or without Cause, (ii)&nbsp;the service of a consultant
to the Company or an Affiliate pursuant to the terms of such consultant&rsquo;s agreement with the Company or an Affiliate, or (iii)&nbsp;the
service of a member of the Board pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate
law of the state in which the Company or the Affiliate is incorporated, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Clawback/Recovery</U>.
The Option will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the
listing standards of any national securities exchange or association on which the Company&rsquo;s securities are listed or as is otherwise
required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose
such other clawback, recovery or recoupment provisions as the Board determines necessary or appropriate, including but not limited to
a reacquisition right in respect of previously acquired Shares or other cash or property upon the occurrence of Cause. No recovery of
compensation under such a clawback policy will be an event giving rise to a right to resign for &ldquo;good reason&rdquo; or &ldquo;constructive
termination&rdquo; (or similar term) under any agreement with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Vesting
and Exercise Schedule</U></B>. The Option will vest and become exercisable as to the number of Shares and on the dates specified in the
Vesting and Exercise Schedule on the cover page&nbsp;to this Agreement, so long as you continue to serve as General Counsel of the Company.
The Vesting and Exercise Schedule is cumulative, meaning that to the extent the Option has not already been exercised and has not expired,
terminated or been cancelled, you or the person otherwise entitled to exercise the Option as provided in this Agreement may at any time
purchase all or any portion of the Shares that may then be purchased under the Vesting and Exercise Schedule. Vesting and exercisability
of the Option may be accelerated during the term of the Option under the circumstances described in Section&nbsp;5(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Changes
in Capitalization, Corporate Transactions, Change in Control</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Adjustments
for Changes in Capitalization</U>. In the event of any equity restructuring (within the meaning of FASB ASC Topic 718 - Stock Compensation)
that causes the per share value of Shares to change, such as a stock dividend, stock split, spinoff, rights offering or recapitalization
through an extraordinary dividend, the Committee shall make such adjustments as it deems equitable and appropriate to (i)&nbsp;the number
and kind of Shares or other securities subject to the Option, and (ii)&nbsp;the exercise price of the Option. In the event of any other
change in corporate capitalization, including a merger, consolidation, reorganization, or partial or complete liquidation of the Company,
such equitable adjustments described in the foregoing sentence may be made as determined to be appropriate and equitable by the Committee
to prevent your dilution or enlargement of rights. In either case, any such adjustment shall be conclusive and binding on you and the
Company. No adjustment shall be made pursuant to this Section&nbsp;5(a)&nbsp;in connection with the conversion of any convertible securities
of the Company, or in a manner that would cause the Option to be subject to adverse tax consequences under Section&nbsp;409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Corporate
Transactions</U>. The following provisions shall apply to the Option in the event of a Change in Control that involves a Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Continuation,
Assumption or Replacement of the Option</U>. In the event of a Corporate Transaction, then the surviving or successor entity (or its
Parent) may continue, assume or replace the Option as of the date of the Corporate Transaction (with such adjustments as may be required
or permitted by Section&nbsp;5(a)), and the Option, or its replacement, if applicable, shall remain outstanding and be governed by the
terms hereof (or a replacement agreement with the same or comparable terms, if applicable). A surviving or successor entity may elect
to continue, assume or replace only a portion of the Option. For purposes of this Section&nbsp;5(b)(1), the Option shall be considered
assumed or replaced if, in connection with the Corporate Transaction and in a manner consistent with Code Sections 409A and 424, either
(i)&nbsp;the contractual obligations represented by the Option are expressly assumed by the surviving or successor entity (or its Parent)
with appropriate adjustments to the number and type of securities subject to the Option and the exercise price thereof that preserves
the intrinsic value of the Option existing at the time of the Corporate Transaction, or (ii)&nbsp;you have been granted a comparable
equity-based award that preserves the intrinsic value of the Option existing at the time of the Corporate Transaction and provides for
a vesting or exercisability schedule that is the same as or more favorable to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acceleration</U>.
If and to the extent that the Option is not continued, assumed or replaced in connection with a Corporate Transaction, then (i)&nbsp;the
Option shall become fully exercisable for such period of time prior to the effective time of the Corporate Transaction as is deemed fair
and equitable by the Committee. The Committee shall provide written notice of the period of accelerated exercisability of the Option
to you. The exercise of the Option shall be conditioned upon the consummation of the Corporate Transaction and shall be effective only
immediately before such consummation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Payment
for the Option</U>. If and to the extent that the Option is not continued, assumed or replaced in connection with a Corporate Transaction,
then the Committee may provide that you must surrender the Option at or immediately prior to the effective time of the Corporate Transaction
in exchange for payments to the holders as provided in this Section&nbsp;5(b)(3). The Committee will not be required to treat all equity
awards similarly for purposes of this Section&nbsp;5(b)(3). The payment for the Option shall be in an amount equal to the difference,
if any, between (i)&nbsp;the fair market value (as determined in good faith by the Committee) of the consideration that would otherwise
be received in the Corporate Transaction for the number of Shares subject to the Option, and (ii)&nbsp;the aggregate exercise price (if
any) for the Shares subject to the Option. Payment shall be made in such form, on such terms and subject to such conditions as the Committee
determines in its discretion, which may or may not be the same as the form, terms and conditions applicable to payments to the Company&rsquo;s
stockholders in connection with the Corporate Transaction, and may include subjecting such payments to vesting conditions comparable
to those of the Option surrendered, or to escrow or holdback terms comparable to those imposed upon the Company&rsquo;s stockholders
under the Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Dissolution
or Liquidation</U>. In the event of a proposed dissolution or liquidation of the Company, the Committee will notify you as soon as practicable
prior to the effective date of such proposed transaction. The Option will terminate immediately prior to the consummation of such proposed
action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Expiration</U></B>.
The Option will expire and will no longer be exercisable at 5:00 p.m.&nbsp; Mountain Time on the earliest of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
expiration date specified on the cover page&nbsp;of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
your termination of Service for Cause;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
the expiration of any applicable period specified in Section&nbsp;3(d)&nbsp;during which the Option may be exercised after your termination
of Service; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
date (if any) fixed for termination or surrender of the Option pursuant to Section&nbsp;5(b)(3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Service
Requirement</U></B>. Except as otherwise provided in Section&nbsp;3(d)&nbsp;above, the Option may be exercised only while you continue
to provide Service to the Company or any Affiliate, and only if you have continuously provided such Service since the date the Option
was granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Exercise
of the Option</U></B>. Subject to Section&nbsp;7, the vested and exercisable portion of the Option may be exercised at any time during
the Option term by delivering a written notice of exercise to the Company at its principal executive office, and by providing for payment
of the exercise price of the Shares being acquired and any related withholding taxes. The notice of exercise, in the form attached to
this Agreement, shall be provided to the Company&rsquo;s Chief Financial Officer. The notice shall state the number of Shares to be purchased,
and shall be signed by the person exercising the Option. If you are not the person exercising the Option, the person submitting the notice
also must submit appropriate proof of his/her right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Payment
of Exercise Price</U></B>. When you submit your notice of exercise, you must include payment of the exercise price of the Shares being
purchased through one or a combination of the following methods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Cash
(including personal check, cashier&rsquo;s check or money order);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">By
delivery to the Company of Shares (by actual delivery or attestation of ownership in a form approved by the Company) already owned by
you that are not subject to any security interest and that have an aggregate Fair Market Value on the date of exercise equal to the exercise
price of the Shares being purchased; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">By
authorizing the Company to retain, from the total number of Shares as to which the Option is being exercised, that number of Shares having
a Fair Market Value on the date of exercise equal to the exercise price for the total number of Shares as to which the Option is being
exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, if the Committee
determines, in any given circumstance, that payment of the exercise price with Shares or by authorizing the Company to retain Shares
is undesirable for any reason, you will not be permitted to pay any portion of the exercise price in that manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Withholding
Taxes</U></B>. You may not exercise the Option in whole or in part unless you make arrangements acceptable to the Company for payment
of any federal, state, local or foreign withholding taxes that may be due as a result of the exercise of the Option. You hereby authorize
the Company (or any Affiliate) to withhold from payroll or other amounts payable to you any sums required to satisfy such withholding
tax obligations. If you wish to satisfy some or all of such withholding tax obligations by delivering Shares you already own or by having
the Company retain a portion of the Shares being acquired upon exercise of the Option, you must make such a request which shall be subject
to approval by the Company. Delivery of Shares upon exercise of the Option is subject to the satisfaction of applicable withholding tax
obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">11.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Delivery
of Certificate</U></B>. As soon as practicable after the Company receives the notice and exercise price provided for above, and determined
that all conditions to exercise, including Sections 10 and 12 of this Agreement, have been satisfied, it shall deliver to the person
exercising the Option, in the name of such person, a certificate or certificates representing the Shares being purchased. The Company
shall pay any original issue or transfer taxes with respect to the issue or transfer of the Shares and all fees and expenses incurred
by it in connection therewith. All Shares so issued shall be fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">12.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Compliance
with Laws</U></B>. The Option may be exercised only if the issuance of Shares upon such exercise complies with all applicable legal requirements,
including compliance with the provisions of applicable federal and state securities laws. If the sale of Shares upon the exercise of
the Option is not registered under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), you shall acknowledge at
the time of exercise that (i)&nbsp;the Shares you are acquiring are deemed &ldquo;restricted securities&rdquo; for purposes of Rule&nbsp;144
under the Securities Act, and you are acquiring the Shares for investment purposes and not with a view to the resale or distribution
of such Shares, and (ii)&nbsp;the Shares you are acquiring may not be sold, pledged or otherwise transferred without (A)&nbsp;an effective
registration or qualification thereof under the Securities Act and the securities laws of any applicable state or other jurisdiction,
or (B)&nbsp;evidence, which may include an opinion of counsel, satisfactory to the Company and its counsel that such registration and
qualification is not required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Transfer
of Option</U></B>. During your lifetime, only you (or your guardian or legal representative in the event of legal incapacity) may exercise
the Option except in the case of a transfer described below. You may not assign or transfer the Option except (i)&nbsp;for a transfer
upon your death in accordance with your will, by the laws of descent and distribution or pursuant to a beneficiary designation, (ii)&nbsp;pursuant
to a qualified domestic relations order, or (iii)&nbsp;with the prior written approval of the Company, by gift, in a form accepted by
the Company. The Option held by any such transferee will continue to be subject to the same terms and conditions that were applicable
to the Option immediately prior to its transfer and may be exercised by such transferee as and to the extent that the Option has become
exercisable and has not terminated in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">14.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>No
Stockholder Rights Before Exercise</U></B>. Neither you nor any permitted transferee of the Option will have any of the rights of a stockholder
of the Company with respect to any Shares subject to the Option until a certificate evidencing such Shares has been issued (or an appropriate
book entry in the Company&rsquo;s stock register has been made). No adjustments shall be made for dividends or other rights if the applicable
record date occurs before your stock certificate has been issued (or an appropriate book entry has been made).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">15.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Choice
of Law</U></B>. This Agreement will be interpreted and enforced under the laws of the state of Delaware (without regard to its conflicts
or choice of law principles).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Binding
Effect</U></B>. This Agreement will be binding in all respects on your heirs, representatives, successors and assigns, and on the successors
and assigns of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Other
Agreements</U></B>. You agree that in connection with the exercise of the Option, you will execute such documents as may be necessary
to become a party to any stockholder, voting or similar agreements as the Company may require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">18.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Restrictive
Legends</U></B>. The Company may place a legend or legends on any certificate representing Shares issued upon the exercise of the Option
summarizing transfer and other restrictions to which the Shares may be subject under applicable securities laws, or other provisions
of this Agreement. You agree that in order to ensure compliance with the restrictions referred to in this Agreement, the Company may
issue appropriate &ldquo;stop transfer&rdquo; instructions to its transfer agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">19.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Transferability
Restrictions and Right to Repurchase</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Until
the earlier to occur of (i)&nbsp;the date upon which the Option is fully vested and may be exercised in full in accordance with Section&nbsp;4
of this Agreement, or (ii)&nbsp;the consummation of an underwritten public offering involving at least twenty percent (20%) of the outstanding
Stock pursuant to an effective registration statement under the Securities Act, you shall not transfer in any manner, or cause or permit
to be transferred in any manner, any Shares issued pursuant to exercise of the Option. Any purported transfer of Shares in violation
of the foregoing provision shall be null and void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Following
termination of your Service for any reason, the Company shall have the right to purchase all Shares that you have acquired or will acquire
under the Option. If the Company decides to exercise its right to purchase the Shares, it will notify you of its intention to purchase
such Shares and will consummate the purchase within ninety (90) days of your termination of Service or, in the case of Shares acquired
after your termination of Service, within ninety (90) days of the date of exercise. The purchase price shall be the Fair Market Value
of the Shares on the date of your termination of Service. The Company&rsquo;s repurchase rights under this Section&nbsp;shall terminate
upon the registration of the Company&rsquo;s Class&nbsp;B common stock under Section&nbsp;12 of the Securities Exchange Act of 1934,
as amended (the &ldquo;Exchange Act&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">20.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Market
Standoff Agreement</U></B>. In connection with any underwritten public offering by the Company of its equity securities, including the
initial public offering of the Company&rsquo;s securities, and upon request of the Company or the underwriters managing such underwritten
offering, you agree not to sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise
dispose of or transfer for value any securities of the Company (other than those included in the registration) without the prior written
consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days)
after the effective date of such registration as may be requested by the Company or such managing underwriters, and to execute an agreement
reflecting the foregoing as may be requested by the underwriters at the time of such public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">21.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Right
of First Refusal</U></B>. Shares that you acquire upon exercise of the Option are subject to the right of first refusal on the part of
the Company that is described in this Section&nbsp;21 until such time as the Company&rsquo;s Stock is registered under Section&nbsp;12
of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Before
any Shares acquired upon the exercise of the Option may be transferred in any manner, including by sale, pledge or other encumbrance,
you must first deliver a written notice (a &ldquo;Transfer Notice&rdquo;) to the Company stating (i)&nbsp;that you desire to transfer
such Shares and (ii)&nbsp;the price and other material terms and conditions of the proposed transfer. The Transfer Notice shall be accompanied
by a certificate from you certifying that you have received a written offer from a third party financially capable of carrying out the
terms of the offer to acquire the Shares at the price and terms set forth in the Transfer Notice, and identifying such third party, including
the name and address. Any notice that does not contain all information required by this Section&nbsp;21(a)&nbsp;shall not be considered
a Transfer Notice for purposes of this Agreement. The Transfer Notice shall be deemed a legally enforceable offer by you to sell the
Shares to which the Transfer Notice refers to the Company pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Within
thirty (30) days after receipt of a Transfer Notice (the &ldquo;Company Period&rdquo;), the Company may elect, by delivering to you a
written notice (a &ldquo;Company Notice&rdquo;) of its election to purchase all or any part (provided that it is a whole number) of the
Shares to which the Transfer Notice refers, on the same terms and conditions specified in the Transfer Notice (or on economically equivalent
terms and conditions specified in the Company Notice). If the Company does not elect to purchase any of the Shares, the Company shall
send a notice to such effect to you prior to the end of the Company Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
a dispute arises between you and the Company concerning the economically equivalent terms and conditions specified in a Company Notice,
the determination of the economic equivalence of such terms and conditions shall be made by an independent investment banking firm selected
by the Company and consented to by you, which consent shall not be unreasonably withheld. You and the Company shall cooperate fully in
assisting any such investment banking firm in making its determination, and such determination shall be made no later than seventy-five
(75) days after the date that the Company received the Transfer Notice. The Company shall bear the cost of such investment banking firm.
If the investment banking firm takes more than seventy-five (75) days to make its determination, the period of time after the seventy-five
(75) days shall be added to the Company&rsquo;s time limit for consummating the transaction as required by Section&nbsp;21(d)&nbsp;of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Company elects to acquire your Shares pursuant to this Section&nbsp;21, you and the Company shall consummate the sale and purchase
of such Shares no later than ninety (90) days after the date that the Company received the Transfer Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">To
the extent the Company does not exercise its rights under this Section&nbsp;21 within the specified time periods, you may, subject to
Section&nbsp;9 of this Agreement, transfer the Shares specified in your Transfer Notice to the third party specified in such Transfer
Notice at the price and on the terms specified in such notice, so long as such transfer is consummated within one hundred twenty (120)
days after the date that the Company received the Transfer Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">You
hereby acknowledge that the right of the Company to purchase your Shares in the manner described in this Section&nbsp;21 is not unreasonable
under the circumstances existing as of the date you execute this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>By signing the cover
page&nbsp;of this Agreement, you agree to all the terms and conditions described above</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following definitions
will apply to this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Affiliate&rdquo;
means any corporation that is a Subsidiary or Parent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Agreement&rdquo;
means the written or electronic agreement containing the terms and conditions applicable to the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Board&rdquo;
means the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Cause&rdquo;
means (i)&nbsp;incompetence or failure or refusal to perform satisfactorily the duties reasonably required of you by the Company (other
than by reason of Disability); (ii)&nbsp;material violation of any law, rule, regulation, court order or regulatory directive (other
than traffic violations, misdemeanors or other minor offenses); (iii)&nbsp;material breach of any fiduciary duty or nondisclosure, non-solicitation,
non-competition or similar obligation owed to the Company or any Affiliate; (iv)&nbsp;engaging in any act or practice that involves personal
dishonesty or demonstrates a willful and continuing disregard for the best interests of the Company and its Affiliates; or (v)&nbsp;engaging
in dishonorable or disruptive behavior, practices or acts which would be reasonably expected to harm or bring disrepute to Company or
any of its Affiliates, their business or any of their customers, employees or vendors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Change
in Control&rdquo; means, unless otherwise provided in an Agreement, one of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
individual, entity or Group (a &ldquo;Person&rdquo;), other than (i)&nbsp;one or more Subsidiaries, or (ii)&nbsp;any employee benefit
plan (or related trust) sponsored or maintained by the Company or any Affiliate, becomes the beneficial owner (within the meaning of
Rule&nbsp;13d-3 under the Securities Exchange Act of 1934) of equity securities of the Company representing more than fifty percent (50%)
of the combined voting power of the Company&rsquo;s then outstanding securities entitled to vote generally in the election of directors
(&ldquo;voting securities&rdquo;), except that (A)&nbsp;any acquisition of Company equity securities by a Person directly from the Company
for the purpose of providing financing to the Company, any formation of a Group consisting solely of beneficial owners of the Company&rsquo;s
voting securities, or any repurchase or other acquisition by the Company of its equity securities that causes any Person to become the
beneficial owner of more than fifty percent (50%) of the Company&rsquo;s voting securities, will not be considered a Change in Control
unless and until, in either case, such Person acquires beneficial ownership of additional Company voting securities after the Person
initially became the beneficial owner of more than fifty percent (50%) of the Company&rsquo;s voting securities by one of the means described
in this clause (A); and (B)&nbsp;a Change in Control will occur if a Person becomes the beneficial owner of more than fifty percent (50%)
of the Company&rsquo;s voting securities as the result of a Corporate Transaction only if the Corporate Transaction is itself a Change
in Control pursuant to subsection (e)(3);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Individuals
who are Continuing Directors cease for any reason to constitute a majority of the members of the Board; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
consummation of a Corporate Transaction unless, immediately following such Corporate Transaction, all or substantially all of the persons
who were the beneficial owners of Company voting securities immediately prior to such Corporate Transaction beneficially own, directly
or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities (or comparable equity
interests) of the surviving or acquiring entity (or its Parent) resulting from such Corporate Transaction in substantially the same proportions
as their ownership of Company voting securities immediately prior to such Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
to the extent that the Option constitutes a deferral of compensation subject to Code Section&nbsp;409A, and if the Option provides for
a change in the time or form of payment upon a Change in Control, then no Change in Control shall be deemed to have occurred unless the
event would also constitute a change in ownership or effective control of, or a change in the ownership of a substantial portion of the
assets of, the Company under Code Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Code&rdquo;
means the Internal Revenue Code of 1986, as amended and in effect from time to time, and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Committee&rdquo;
means the Board or a committee of the Board comprised of two (2)&nbsp;or more Non-Employee Directors designated by the Board to administer
the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Company&rdquo;
means SomaLogic,&nbsp;Inc., a Delaware corporation, or any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Continuing
Director&rdquo; means an individual (A)&nbsp;who is, as of the effective date of the Option, a director of the Company, (B)&nbsp;who
is elected as a director of the Company subsequent to the effective date hereof pursuant to a nomination or board representation right
of preferred stockholders of the Company, or (C)&nbsp;who becomes a director of the Company after the effective date hereof and whose
initial election, or nomination for election by the Company&rsquo;s stockholders, was approved by at least a majority of the then Continuing
Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Corporate
Transaction&rdquo; means (i)&nbsp;a sale or other disposition of all or substantially all of the assets of the Company, or (ii)&nbsp;a
merger, consolidation, share exchange or similar transaction involving the Company, regardless of whether the Company is the surviving
corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Disability&rdquo;
means (A)&nbsp;any permanent and total disability under any long-term disability plan or policy of the Company or its Affiliates that
covers you, or (B)&nbsp;if there is no such long-term disability plan or policy, &ldquo;total and permanent disability&rdquo; within
the meaning Code Section&nbsp;22(e)(3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Employee&rdquo;
means an employee of the Company or an Affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Fair
Market Value&rdquo; means the fair market value of a Share determined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Shares are readily tradable on an established securities market (as determined under Code Section&nbsp;409A), then Fair Market Value
will be the closing sales price for a Share on the principal securities market on which it trades on the date for which it is being determined,
or if no sale of Shares occurred on that date, on the next preceding date on which a sale of Shares occurred, as reported in The Wall
Street Journal or such other source as the Committee deems reliable; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Shares are not then readily tradable on an established securities market (as determined under Code Section&nbsp;409A), then Fair
Market Value will be determined by the Committee as the result of a reasonable application of a reasonable valuation method that satisfies
the requirements of Code Section&nbsp;409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Group&rdquo;
means two or more persons acting as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding
or disposing of securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Incentive
Stock Option&rdquo; means any Stock Option designated as such and granted in accordance with the requirements of Code Section&nbsp;422.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Non-Employee
Director&rdquo; means a member of the Board who is not an Employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Non-Statutory
Stock Option&rdquo; means a Stock Option other than an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Parent&rdquo;
means a &ldquo;parent corporation,&rdquo; as defined in Code Section&nbsp;424(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Service&rdquo;
means the provision of services by you to the Company or any Affiliate in any Service Provider capacity. A Service Provider&rsquo;s Service
shall be deemed to have terminated either upon an actual cessation of providing services or upon the entity for which the Service Provider
provides services ceasing to be an Affiliate. Except as otherwise provided in this Agreement, Service shall not be deemed terminated
in the case of (i)&nbsp;any approved leave of absence; (ii)&nbsp;transfers among the Company and any Affiliates in any Service Provider
capacity; or (iii)&nbsp;any change in status so long as the individual remains in the service of the Company or any Affiliate in any
Service Provider capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Service
Provider&rdquo; means an Employee, a Non-Employee Director, or any consultant or advisor who is a natural person and who provides services
(other than in connection with (i)&nbsp;a capital-raising transaction or (ii)&nbsp;promoting or maintaining a market in Company securities)
to the Company or any Affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Share&rdquo;
means a share of Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Stock&rdquo;
means the Class&nbsp;B common stock, $0.01 par value, of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Stock
Option&rdquo; means a right granted to purchase a specified number of Shares at a specified price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;Subsidiary&rdquo;
means a &ldquo;subsidiary corporation,&rdquo; as defined in Code Section&nbsp;424(f), of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Non-Statutory Stock Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">____________________, 20____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SomaLogic,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2945 Wilderness Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Boulder, Colorado 80301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby exercise the following
option (the &ldquo;Option&rdquo;) granted to me with respect to the number of shares of Class&nbsp;B common stock of SomaLogic,&nbsp;Inc.
(the &ldquo;Company&rdquo;) indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5in"><B>Name:</B></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date of Grant of Option:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Exercise Price Per Share:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Number of Shares With Respect to Which&#8239;the
    Option is Hereby Exercised:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total Exercise Price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Enclosed with this Notice
                                            is a check, cashier&rsquo;s check or money order in the amount of the Total Exercise Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Enclosed with this Notice
                                            is a certificate evidencing unencumbered Shares (duly endorsed in blank) having an aggregate
                                            Fair Market Value equal to or in excess of the Total Exercise Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">I
                                            elect to pay the Total Exercise Price through a reduction in the number of Shares to be delivered
                                            to me upon this exercise of the Option.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this exercise,&nbsp;I represent,
warrant and acknowledge as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">I
                                            will provide for the payment to the Company, in a manner agreed to by the Company, of the
                                            amount of any required withholding taxes in connection with this exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">I
                                            am acquiring the Shares as a result of this exercise of the Option for my own account, and
                                            acknowledge that the Shares have not been registered under the Securities Act of 1933, as
                                            amended (the &ldquo;Securities Act&rdquo;), and are deemed to constitute &ldquo;restricted
                                            securities&rdquo; under Rule&nbsp;144 of the Securities Act. I have no present intention
                                            of distributing or selling such Shares, and will transfer them only as permitted under applicable
                                            federal and state securities laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">I
                                            am the owner of all Shares delivered with this Notice free and clear of all liens, security
                                            interests and other restrictions or encumbrances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please issue a certificate (the &ldquo;Certificate&rdquo;)
for the number of Shares with respect to which the Option is being exercised (or the net number of Shares if the Total Exercise Price
and/or applicable withholding taxes are being paid through a reduction in the number of Shares to be delivered to me) in the name of
the person indicated below and deliver the Certificate to the address indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name in Which to Issue Certificate:</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Address to Which Certificate Should&#8239;be
    Delivered:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Principal Mailing Address for&#8239;Holder
    of the Certificate (if&#8239;different from above):</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name, please print</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Social Security Number</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>tm243480d1_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Exhibit&nbsp;107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form&nbsp;Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Standard BioTools Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Table 1: Newly Registered Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2pt; border-left: Black 1pt solid; text-align: center; width: 19%"><FONT STYLE="font-size: 10pt">Security<BR> Type</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2pt; border-left: Black 1pt solid; text-align: center; width: 15%">Security<BR> Class<BR> Title</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2pt; border-left: Black 1pt solid; text-align: center; width: 12%">Fee<BR> Calculation<BR> Rule</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2pt; border-left: Black 1pt solid; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt">Amount<BR> Registered<BR> (1)(2)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2pt; border-left: Black 1pt solid; text-align: center; width: 12%">Proposed<BR> Maximum<BR> Offering<BR> Price&nbsp;Per<BR> Unit</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2pt; border-left: Black 1pt solid; text-align: center; width: 12%">Maximum<BR> Aggregate<BR> Offering<BR> Price</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2pt; border-left: Black 1pt solid; text-align: center; width: 10%">Fee<BR> Rate</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2pt; border-right: black 1pt solid; border-left: Black 1pt solid; text-align: center; width: 10%">Amount&nbsp;of<BR> Registration<BR> Fee</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Equity&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">Common Stock,<BR> $0.001 par value per<BR> share</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">457(h)&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">527,927 (3)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$2.12 (4)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$1,119,205.24</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$0.00014760&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$165.20</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">Common Stock,<BR> $0.001 par value per<BR> share</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">457(h)&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">4,287,055 (5)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$4.38 (6)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$18,777,300.90</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$0.00014760&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$2,771.53</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">Common Stock,<BR> $0.001 par value per<BR> share</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">457(h)&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">2,660,688 (7)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$9.38 (8)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$24,957,253.44</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$0.00014760&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$3,683.70</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">Common Stock,<BR> $0.001 par value per<BR> share</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">457(h)&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">33,749 (9)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$1.82 (10)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$61,423.18</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$0.00014760&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$9.07</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">Common Stock,<BR> $0.001 par value per<BR> share</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">457(h)&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">1,860,582 (11)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$4.30 (12)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$8,000,502.60</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$0.00014760&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$1,180.88</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">Common Stock,<BR> $0.001 par value per<BR> share</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">457(h)&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">930,290 (13)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$4.30 (14)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$4,000,247.00</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$0.00014760&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$590.44</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">Common Stock,<BR> $0.001 par value per<BR> share</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">457(h)&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">426,385 (15)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$7.30 (16)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$3,112,610.50</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$0.00014760&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$459.43</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Equity</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">Common Stock,<BR> $0.001 par value per<BR> share</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">457(h)&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">110,476 (17)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$7.30 (18)</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$806,474.80</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$0.00014760&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">$119.04</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 2pt 5pt; border-right: black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: center">Total Offering Amounts</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">$60,835,017.66</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">$8,979.29</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; vertical-align: top; text-align: center">Total Fees Previously Paid</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5pt; border-left: Black 1pt solid; border-right: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">&mdash;</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; vertical-align: top; text-align: center">Total Fee Offsets</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-right: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">&mdash;</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: center">Net Fee Due</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5pt; border-left: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">$8,979.29</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">The number of shares <FONT STYLE="background-color: white">of common stock, par value $0.001 per share
(&ldquo;<U>Common Stock</U>&rdquo;) of Standard BioTools Inc. (the &ldquo;<U>Registrant</U>&rdquo;) stated above consists of shares of
Common Stock available for issuance pursuant to the exercise of options to purchase shares of Common Stock granted to former employees,
directors and consultants of SomaLogic,&nbsp;Inc. (&ldquo;<U>SomaLogic</U>&rdquo;) under the SomaLogic,&nbsp;Inc. 2009 Equity Incentive
Plan, the SomaLogic,&nbsp;Inc. 2017 Equity Incentive Plan and the SomaLogic,&nbsp;Inc. 2021 Omnibus Incentive Plan (collectively, the
 &ldquo;<U>SomaLogic Equity Plans</U>&rdquo;), as well as pursuant to that certain Non-Statutory Stock Option Agreement, dated June&nbsp;6,
2014, Non-Statutory Stock Option Agreement, dated November&nbsp;19, 2018, Non-Statutory Stock Option Agreement, dated September&nbsp;1,
2020, Non-Statutory Stock Option Agreement, dated August&nbsp;6, 2021 and Non-Statutory Stock Option Agreement, dated August&nbsp;20,
2021 (collectively, the &ldquo;<U>Non-Statutory Stock Option Agreements</U>&rdquo;). In addition, pursuant to Rule&nbsp;416(a)&nbsp;under
the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), this Registration Statement shall also cover any additional
shares of the Registrant&rsquo;s Common Stock that become issuable pursuant to the exercise of options to purchase shares of Common Stock
under the SomaLogic Equity Plans or the Non-Statutory Stock Option Agreements by reason of an event such as any stock split, stock dividend
or similar adjustment effected without the Registrant&rsquo;s receipt of consideration that increases the number of the outstanding shares
of Common Stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(2)</TD><TD STYLE="text-align: justify">Pursuant to that certain Agreement and Plan of Merger, dated October&nbsp;4, 2023, by and among the Registrant,
Martis Merger Sub,&nbsp;Inc. and SomaLogic (the &ldquo;<U>Merger</U>&rdquo;), each option to purchase SomaLogic common stock (a &ldquo;<U>SomaLogic
Option</U>&rdquo;), whether vested or unvested, that was outstanding immediately prior the effective time of the Merger (the &ldquo;<U>Effective
Time</U>&rdquo;), was converted into an option to acquire the number of shares of Common Stock of the Registrant equal to the product
of (i)&nbsp;the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii)&nbsp;1.11
(the &ldquo;<U>Exchange Ratio</U>&rdquo;), rounded down to the nearest whole number of shares of the Registrant&rsquo;s Common Stock,
at an exercise price equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio,
rounded up to the nearest whole cent.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(3)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock reserved for issuance upon the exercise of outstanding SomaLogic Options
granted under the SomaLogic,&nbsp;Inc. 2009 Equity Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(4)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(h)&nbsp;under
the Securities Act, and based upon a price of $2.12 per share, which is the weighted-average exercise price for SomaLogic Options outstanding
under the SomaLogic,&nbsp;Inc. 2009 Equity Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(5)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock reserved for issuance upon the exercise of outstanding SomaLogic Options
granted under the SomaLogic,&nbsp;Inc. 2017 Equity Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(6)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(h)&nbsp;under
the Securities Act, and based upon a price of $4.38 per share, which is the weighted-average exercise price for SomaLogic Options outstanding
under the SomaLogic,&nbsp;Inc. 2017 Equity Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(7)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock reserved for issuance upon the exercise of outstanding SomaLogic Options
granted under the SomaLogic,&nbsp;Inc. 2021 Omnibus Incentive Plan.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(8)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(h)&nbsp;under
the Securities Act, and based upon a price of $9.38 per share, which is the weighted-average exercise price for SomaLogic Options outstanding
under the SomaLogic,&nbsp;Inc. 2021 Omnibus Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(9)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock reserved for issuance upon the exercise of outstanding SomaLogic Options
granted under the Non-Statutory Stock Option Agreement, dated June&nbsp;6, 2014.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(10)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(h)&nbsp;under
the Securities Act, and based upon a price of $1.82 per share, which is the exercise price for SomaLogic Options outstanding under the
Non-Statutory Stock Option Agreement, dated June&nbsp;6, 2014.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(11)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock reserved for issuance upon the exercise of outstanding SomaLogic Options
granted under the Non-Statutory Stock Option Agreement, dated November&nbsp;19, 2018.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(12)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(h)&nbsp;under
the Securities Act, and based upon a price of $4.30 per share, which is the exercise price for SomaLogic Options outstanding under the
Non-Statutory Stock Option Agreement, dated November&nbsp;19, 2018.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(13)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock reserved for issuance upon the exercise of outstanding SomaLogic Options
granted under the Non-Statutory Stock Option Agreement, dated September&nbsp;1, 2020.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(14)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(h)&nbsp;under
the Securities Act, and based upon a price of $4.30 per share, which is the exercise price for SomaLogic Options outstanding under the
Non-Statutory Stock Option Agreement, dated September&nbsp;1, 2020.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(15)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock reserved for issuance upon the exercise of outstanding SomaLogic Options
granted under the Non-Statutory Stock Option Agreement, dated August&nbsp;6, 2021.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(16)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(h)&nbsp;under
the Securities Act, and based upon a price of $7.30 per share, which is the exercise price for SomaLogic Options outstanding under the
Non-Statutory Stock Option Agreement, dated August&nbsp;6, 2021.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(17)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock reserved for issuance upon the exercise of outstanding SomaLogic Options
granted under the Non-Statutory Stock Option Agreement, dated August&nbsp;20, 2021.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(18)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(h)&nbsp;under
the Securities Act, and based upon a price of $7.30 per share, which is the exercise price for SomaLogic Options outstanding under the
Non-Statutory Stock Option Agreement, dated August&nbsp;20, 2021.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm243480d1_s3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm243480d1_s3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G . # 2(  A$! Q$!_\0
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MW^[B N/]GYAC=D8SGH<C/!K#O]9T_3XI;V_U&PTZ #=)->M]C4*HP"9"<#Y
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MY^M4N&.$J6#AAJ> ^JRB[JI_-:,H\GSNI?\ ;I^Z?_!)S_@H=)\&_$\/P?\
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MB/0Y]>;P[/=X^9RM^PC/\$;(O\(KYZ_:JO-;_P""@?\ P5Z\&?#3PP^J>*/
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M^2MUI]IKFAZ'J&GB[/W]][874G7Y2=A^[49/P_2S+AZ6(7\=8E*7^%0J7_\
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M/!FJ?#WQ;KE_#I>G75Y_RPNV;9Y3'[-:<2$JP_T>, .H&\?O&_7;]LKX_?\
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M_P#!:[]@PO&(OBSIS$JV^(W>DJR\G&1YN<GAAAAD$>]?YWJR2VRM M]I84\
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MK5^B99Q+D^.HQ7>-]'MLM?O]3S)X#$4TG55XMV7777R?1,X#2-?U;P[)>?\
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FWR;3[=T:$*+'N1?NJ1C\1D_J:FHHK,V"BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm243480d1_s3img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm243480d1_s3img002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "+ +$# 2(  A$! Q$!_\0
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MJ5TL$K8X/[\;@TAQ\L4>Z4]D.1GX:5.$%><HP7>3Y5][:\SZ;#M8N=*GA?\
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M'@'0%\;QZG;6]K?3)?:A807-_'LT&]M+QIU\0/;^5*L0E,^Z(?D;_P %#/\
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MANA*J=H#?G.G_! ;_@G^-DC>"/$C3P37<ELP\0(J*)C\F^:2RNK@\$$=3U!
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MZHE%->35UK:Z:7@YQ1S&FKTJLI)_RW=ON_KY:OQ<_P#!>3_@H@OW/B!X9/\
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%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !U %\# 2(  A$! Q$!_\0
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MTV_G\Z[LX9I,;=SC)QZ57_X170_^@9;?]\UT1K)*QY&)RBI5K2J*2U?F<_\
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)ZUT0Z444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm243480d1_ex5-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm243480d1_ex5-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- #\# 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
